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6abstraCt
Background and aims. Standard treatment of recurrent Clostridium difficile 
infection (CDI) with antibiotics leads to recurrences in up to 50% of patients. 
In recent years the incidence and mortality of Clostridium difficile (C. difficile) 
enteritis have increased. Nevertheless, C. difficile has rarely been isolated in extra-
intestinal infections. The aims of the study were to investigate efficacy of rifaximin, 
metronidazole, fecal microbiota transplantation (FMT) and Clostridium difficile 
immune whey (CDIW) in the treatment of recurrent CDI and to characterize clinical 
feature and risk factors for extra-intestinal CDI.
Subjects and methods. Study I was a prospective, randomized, double-blind 
study designed to compare CDIW with metronidazole for treatment of laboratory-
confirmed, mild to moderate episodes of  recurrent CDI. CDIW was manufactured by 
immunization of cows in their gestation period with inactivated C. difficile vaccine. 
The resulting colostrum was processed, immunoglubulins were concentrated and 
the end-product containing high titres of C. difficile immunoglobulin was used 
as CDIW. 20 patients received metronidazole at a dosage of 400 mg t.i.d. and 18 
patients CDIW 200 ml t.i.d. Study II was a retrospective review of  70 patients with 
recurrent CDI who had undergone fecal transplantation. FMT was performed at 
colonoscopy by infusing fresh donor feces into cecum. Before transplantation, the 
patients had whole-bowel lavage with polyethylene glycol solution. Study III was 
a retrospective study of 32 patients who were treated with rifaximin for recurrent 
CDI. In Study IV extra-intestinal CDIs were searched for in an electronic database 
of all C. difficile positive isolates found during a 10-year period. The medical records 
were reviewed retrospectively. Disease severity and co-morbidities of the patients 
were evaluated using Horn disease severity and Charlson co-morbidity indexes.
Results. In Study I, 10 weeks after the beginning of treatment, sustained 
responses were observed in 11 (55%) of 20 patients receiving metronidazole and 10 
(56%) of 18 patients treated with CDIW. In Study II, 12 weeks after FMT, 66 (94%) 
of 70 patients had a favourable response. In Study III, 12 weeks after rifaximin 
treatment 17 (53%) of 30 patients had no relapse. In Study IV extra-intestinal CDI 
was found in 31 patients who comprised 0.17% of all CDIs. One-year mortality 
rate was 36% and it correlated with the severity of underlying diseases.
7Conclusions. CDIW was as effective as metronidazole in the prevention of CDI 
recurrences and it was well tolerated. FMT through colonoscopy seems to be an 
effective treatment also for recurrent CDI caused by the virulent C difficile 027 strain. 
The MIC value of rifampin seemed to predict the response to rifaximin treatment. 
Extra-intestinal CDIs occur mainly in hospitalized patients with significant co-
morbidities. Extra-intestinal CDIs in the abdominal area may result either from 
intestinal perforation after infection or after intestinal surgery. C. difficile may reach 
distant sites via bacteremia. Mortality in extra-intestinal CDIs is associated with 
the severity of underlying diseases.
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9abbreviations
AAD antibiotic-associated diarrhea
AAHC antibiotic-associated haemorrhagic colitis
ACG American College of Gastroenterology
ADM agar dilution method 
AIM agar incorporation method 
ANTI-TNF anti-tumor necrosis factor
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CDI Clostridium difficile infection      
CDIW Clostridium difficile immune whey
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t.i.d. three times in a day
VRE vancomycin resistant enterococcus
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1 introduCtion
Clostridium difficie infection (CDI)  is a common cause of both community- and 
hospital-acquired diarrhea, usually occurring after exposure to antibiotics. During 
the past few years, C. difficile infection has become more frequent, more severe, 
more refractory to standard treatment, and more likely to relapse (Gravel et al. 2009, 
Zillberg et al. 2010, Pepin et al. 2005¹, Musher et al. 2005). Recurrent CDI increases 
the average length of hospitalization and cost of treatment. In addition, patients often 
become frustrated by the consistent reappearance of symptoms and the repeated 
need for treatment. Also recurrent CDI is associated with severe complications of 
megacolon, perforation, shock, or death (Pepin et al. 2006).
Current treatment with metronidazole or vancomycin against CDI is suboptimal, 
especially in terms of high recurrence rates. Both of these antibiotics alter the 
normal gut flora that provides colonization resistance against C. difficile (Chang 
et al. 2008). A number of empirical approaches have been used to treat recurrent 
CDI.  New antibiotics have been introduced including rifaximin (Johnson et al. 
2007), nitazoxanide (Musher et al. 2006) and fidaxomicin (Louie et al. 2009). 
Passive immune therapy has been used as intravenous immunoglobulin (Wilcox 
2004). Also, probiotic regimens with Saccharomyces boulardii (Surawicz et al. 
2000) and Lactobacillus (Wullt et al. 2003) have been used. All these currently 
available treatment modalities have limited efficacy. Data are lacking to support 
any particular treatment strategy.
Treatment of CDI enteritis is shifting towards local therapy such as per oral 
non-absorbable antibiotics vancomycin, rifaximin, and fidoxomycin. (Lo Vecchi 
and Zacur 2012). Although C. difficile enteritis is the most frequent presentation 
of CDI, C. difficile causes infections also outside the intestine. In clinical practice, 
a finding of C. difficile in an extra-intestinal site is often a surprise. Evaluation of 
the significance of the finding may not always be straightforward especially when 
C. difficile is found together with other microbes. 
After the appearance of ribotype 027 in Finland (Lyytikäinen et al 2007) there 
were more patients with relapses of CDI and the relapses were also more difficult 
to treat with conventional antibiotic therapy for CDI. This encouraged the use of 
Clostridium difficile immune whey (CDIW), rifaximin and fecal transplantation for 
recurrent CDI, and they became a treatment option for selected patients. 
The present studies were undertaken to gain insight into the effect and safety of 
these treatment modalities. We conducted a nationwide, double-blind, multicentre 
study comparing CDIW and metronidazole in recurrent CDI (RCDI). We also 
conducted a retrospective study of 70 patients with RCDI treated with colonoscopy 
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administered fecal microbiota transplantation (FMT) in 5 different centers. The 
FMTs were performed using a standard method in all centers. We retrospectively 
evaluated the records of 32 patients who were treated with rifaximin for RCDI. 
We also performed a systematic analysis of all consecutive extra-intestinal CDIs 
during 10 years time in order to characterize predisposing factors, clinical features 
and outcomes of these infections. In addition, clinical features and risk factors of 
extra-intestinal CDI were characterized.
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2 review of the literature
2.1 DISCOveRy Of C. diffiCile AnD ItS ROLe  
In AntIbIOtIC-ASSOCIAteD DIARRheA
In 1935, Hall and O’Toole first isolated a gram-positive, cytotoxin producing 
anaerobic bacterium from the normal intestinal flora of newborn infants (Hall 
and O’Toole 1935).They named it Bacillus difficilis to reflect the difficulties they 
encountered in its isolation and culture. These investigators also showed that this 
organism produced a toxin that was highly lethal to mice. Almost 40 years later the 
species now known as C. difficile  was identified as the etiological agent of antibiotic-
associated  pseudomembranous colitis (Bartlett et al. 1978). Paradoxically, the major 
pathologic feature of antibiotic associated colitis, pseudomembranous colitis, was 
first described in 1893 (Finney 1893) in the preantibiotic era.
Antibiotic-associated diarrhea (AAD) became a well-recognized complication of 
antibiotic use shortly after the introduction of these agents in the early 1950s. The 
incidence of AAD varies from 5% to 39% depending upon the population (McFarland 
1998) and type of antibiotic (Bartlett 2002). The rates of diarrhea associated with 
parenterally administered antibiotics, especially those with enterohepatic circulation, 
are similar to rates associated with orally administered agents (Wiström et al 2001).
In patients who develop AAD due to C. difficile, administration of antibiotics 
either allows colonization by C. difficile after ingestion of environmental spores or 
permits overgrowth of indigenous C. difficile (Wilson 1993). Approximately 20-30% 
of cases of AAD, 50-75 % of those with antibiotic-associated colitis, and in more 
than 90 % of those with antibiotic associated pseudomembranous colitis are due 
to C. difficile infection (CDI) (McFarland 1998, Bartlett 2002).
The etiology of AAD and colitis that is not caused by C. difficile is poorly 
understood. Candida spp, particularly among elderly hospitalized patients, 
enterotoxigenic Clostridium perfingens and Klebsiella oxytoca has been cited as 
possible cause of AAD (Levine et al. 1995, Asha and Wilcox 2002). Recent antibiotic 
exposure has emerged as a distinct factor of in both sporadic cases and outbreaks 
of salmonellosis (Neal et al 1994). These organisms are rare causes, however, and 
70%–80% of AAD cases have no established microbial pathogen. Many cases are 
probably episodes of osmotic diarrhea resulting from the failure of the fecal flora to 
catabolize carbohydrates (Young VB and Schmidt 2004) or changes in short-chain 
fatty acid metabolism (Hove et al 1996).
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2.2 DefInItIOn Of CDI
The Society for Healthcare Epidemiology of America/Infectious Diseases Society of 
America (SHEA/IDSA) guidelines (Cohen 2012 et al) define CDI in the following 
manner: A case definition of CDI should include the presence of symptoms (usually 
diarrhea) and either a stool test result positive for C. difficile toxins or toxigenic 
C. difficile, or colonoscopic findings demonstrating pseudomembranous colitis. In 
the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) 
guideline (Bauer et al. 2009) CDI is defined as  a clinical picture compatible with 
CDI and microbiological evidence of toxin-producing C. difficile in stool without 
evidence of another cause of diarrhoea or pseudomembranous colitis. CDI may be 
further defined according to the time of symptom onset and history of hospitalization 
(Table 1).
table 1  Definition of CDI 
type of case definition
Health-care facility-onset
health-care facility
associated (HO-HCFA)
Occurs when onset of symptoms 3 days after admission to  
a health-care facility
Community onset healthcare
facility associated
(CO-HCFA)
Onset of symptoms within 4 weeks after being discharged 
from a health-care facility.
Community associated (CA) Occurs when onset of symptoms occurs outside a health-care 
facility or < 3 days after admission to a health-care facility and
has not been discharged from a healthcare facility in the 
previous 12 weeks
Indeterminate or unknown
onset (ID)
CDI develops after being discharged from a health-care facility 
4 – 12 weeks previously
Recurrent CDI Episode of CDI that occurs 8 weeks after the onset of a 
previous episode, provided the symptoms from the previous 
episode resolved
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2.3 ePIDemIOLOgy Of CDI 
2.3.1 ChAngIng ePIDemIOLOgy
Since the early 2000s, the epidemiology of CDI has changed dramatically across 
the Europe, United States and Canada; an increase in overall incidence has been 
highlighted by outbreaks of more-severe disease than previously observed (McDonald 
et al. 2006, Redelings et al 2007, Burckhardt et al. 2008, Gravel et al. 2009). 
CDI outbreaks often correlate with increasing total antimicrobial consumption, 
introduction of a particular strain of C. difficile, poor attention to environmental 
cleaning and waning compliance with good infection control practices (Owens et 
al. 2008).
The rising rates of CDI have been attributed to the precence of ribotype 027 
strain but are not limited to the spread of this strain. Most of the evidence suggesting 
that 027 strains are more virulent and associated with more severe disease are 
derived from studies conducted during outbreak settings. In contrast, 027 strains 
were not found to be more virulent in studies conducted in nonepidemic settings or 
in settings where the prevalence of 027 remains low (Sirard et al. 2011). Historic and 
recent isolates of the 027 strain differ in their level of resistance to fluoroquinolones; 
more recent isolates are more highly resistant to these drugs (McDonald et al. 
2005). This, coupled with increasing use of the fluoroquinolones likely promoted 
dissemination of a once uncommon strain. In some countries in Europe the 
prevalence of the 027 strain is now decreasing (Hensens et al. 2009, Bauer et al. 
2011). Depending on the country, other emerging PCR-ribotypes have also been 
reported and include 012, 017, 019, 036, 078 and 153 (Knetsch et al. 2011, Dawson 
et al. 2009). Ribotype 078 causes disease both in animals, particularly calves and 
pigs, and humans. Studies to date have shown a high degree of genetic relatedness in 
the animal and human strains (Goorhuis et al. 2008). In the Netherlands, patients 
infected with ribotype 078 were younger (67.4 versus 73.5 years) and had community 
associated disease more frequently (17.5% versus 6.7%) than patients infected with 
ribotype 027 (Debast et al. 2008).
It appears that increases in the rate of CDI hospital discharges in USA may 
be leveling off, with a 2.5% decrease in the point estimate from 8.75 per 1000 
discharges in 2008 to 8.53 per 1000 discharges in 2009 (Lucado et al 2012).  The 
same phenomenon is also observed in Finland (Kanerva et al 2013). The first case of 
fatal C. difficile ribotype 027-associated disease was detected in Finland in October 
2007 (Lyytikäinen et al 2007). Since then, the National Public Health Institute 
intensified the surveillance and control of CDI. In January 2008, laboratory-
based surveillance of C. difficile was initiated as a part of the Finnish National 
Infectious Disease Register (NIDR) and enhanced surveillance of hospitalized 
patients with CDI by the Finnish Hospital Infection Programme (SIRO). Both 
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the population-based incidence of C. difficile and the enhanced surveillance of 
hospitalized patients with CDI showed a decrease by one-quarter during the first 
years of surveillance in 2008-2010 (Kanerva et al. 2013). Since then, the annual 
incidence is stabilized, as seen in Figure 1. In Finland 5257 toxin positive patients 
were reported for National Institute for Health and Welfare in 2012.
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figure 1  Annual incidence of CDI in Finland. Source: National Institute for Health and Welfare. 
2.3.2 COmmunIty ASSOCIAteD CDI
The incidence of CDI might be increasing among persons living in the community, 
including, but not limited to, healthy persons without recent healthcare contact 
(Kyne et al. 1998, Johal et al. 2004, Dial et al.2005). Data from the United States, 
Canada, and Europe suggest that approximately 20%–27% of all CDI cases are 
community associated, with an incidence of 20–30 per 100 000 population (Wilcox 
et al. 2008, Kutty et al.2010, Lambert et al. 2009). Compared with hospital acquired 
infections, patients with community associated CDI are younger, healthier and 
less likely to have been exposed to antibiotics (Khanna 2012²). These cases stress 
the importance of considering CDI in the differential diagnosis of any patient with 
diarrhea, even in the absence of traditional risk factors. The high incidence of CDI in 
health care facilities compared with the community presumably results from the high 
density of individuals prone to CDI, classically, elderly patients with comorbidity, 
who may serve as a reservoir in which C. difficile can amplify.
Possible community sources for CDI include soil, water, pets, meats and 
vegetables (Hensgens et al. 2012²). Direct transmission of C. difficile from 
animals, food or the environment to humans has not been proven, although similar 
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ribotypes are found. As no outbreaks of CDI have been reported among humans 
in the community, host factors that increase vulnerability to CDI might be of more 
importance than increased exposure to C. difficile.
2.3.3 buRDen Of CDI
CDI is a leading cause of hospital associated infectious diarrhea (McFarland et al 
1989). Recent data from 28 community hospitals in the southern United States 
suggest that C. difficile has replaced methicillin-resistant Staphylococcus aureus 
as the most common cause of healthcare-associated infection (Miller et al 2011¹). 
The annual cost of hospital care for patients with CDI totals to approximately $3.2 
billion in the USA (O’Brien et al. 2007), although a significant percentage of CDI 
cases are missed because clinicians often fail to request tests for C. difficile toxins 
in cases of unexplained diarrhoea. In a Finnish study RCDI was associated with 
significantly longer length of stay (LOS) and higher costs compared to the average 
CDI population (Agthe et al 2012). The main cost driver between the groups was 
LOS (Figure 2, Agthe et al. 2012).
a. Patient day 829 €
b. Surgery 383 €, Endoscopy 1161 €
c. incl. blood-, urine, stool-samples and RTG performed due to CDI infection
d. Metronidazole, vancomycin and fluconazol
e. cost/day 6.46 € (gloves, gowns, time used for changing gloves and gowns)
Length of stay due to CDIa
Surgery and endoscopyb
Laboratory and RTGc
Medicationd
Isolatione
34€
25€
116€
172€
1,967€
36€
115€
347€
0€
6,300€
Not recurrent case (n=67)
2,315€
Recurrent case (n=5)
6,797€Total cost:
Resource:
figure 2  Healthcare costs for recurrent and not recurrent case (average/patient)
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Data from the European survey showed that the overall mortality rate was 
22%, with CDI being directly responsible for c. 2% of all deaths and a contributor 
to death in a further 7% of cases (Bauer et al. 2011). The overall mortality rate at 
day 30 was similar, 23 %, in a Canadian study (Pepin et al. 2005³).
2.3.4 CDI In SPeCIAL POPuLAtIOnS
Children 
As among adults, the epidemiology of CDI in children has been changing over 
the past decade. Historically, health care–associated diarrhea among children was 
attributed to viral pathogens (Langley et al 2002). Kim and colleagues showed a 
steady increase in the annual incidence of CDI among paediatric inpatients, from 
2.6 to 4 cases per 1000 admissions in 22 US hospitals over the 5-year period to 
2006 (Kim et al 2006). Also rates of pediatric CDI-related hospitalizations increased 
substantially between 1997 and 2006, from 0.724 to 1.28 per 1000 hospitalizations 
(Zillberg et al 2010). The increase was mainly due to high rates among children 
aged 1-4 years and non-newborns less than a year old. Colonisation with C. difficile 
in children appears to occur soon after birth and rises to very high levels (70%) at 
one year (Al-Jumaili et al. 1984), with high carriage rates particularly associated 
with hospitalisation (Enocha et al. 2011). Because of this it is difficult to determine 
whether CDI-related hospitalizations in this age group represent true infection or 
colonization. Asymptomatic carriage diminishes with age as the lower intestinal 
microbiota becomes established, usually by age of 2 years (Hafiz and Oakely 2012). 
In the 24–36-month age group, colonization was 6 % (Rousseau et al. 2012), a 
value close to that observed in adults. In the same study toxigenic clones were 
found during several months, in contrast with the succession of clones found in 
infants colonized by nontoxigenic strains. Symptomatic CDI appears to be strongly 
linked to the presence of co-morbidities such as haematological malignancies, 
immunosuppression and bowel disorders (Sandora et al. 2011, Tai et al. 2011). 
Reported rates of recurrence among children have been similar to those in adults 
(Kim et al. 2012).
Recently in a large multicenter retrospective analysis children who develop CDI 
after admission to the hospital have a  >6-fold higher mortality rates than do controls 
with similar underlying disease and risk factors (Sammons et al 2013). In addition, 
children with CDI have significantly longer LOS and incur more total hospital costs 
than matched controls. Contact with infants aged <2 years has been linked with 
CDI in adults (14% versus 2%; P < 0.02) with community acquired disease (Wilcox 
et al. 2008). Still, the significance and outcomes associated with CDI, as well as the 
optimal diagnosis and treatment, remain poorly defined among children.
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Peripartum Women
The estimated CDI incidence among peripartum women increased from 0.4 to 
0.7 per 100,000 deliveries in USA from 1998 to 2006 (Kuntz et al. 2010). 67 % 
of CDI cases were observed in women who underwent Cesarean section. Women 
undergoing a Cesarean section tend to have significantly longer hospital stays than 
do women undergoing a vaginal delivery, placing them at increased risk of exposure 
to a nosocomial CDI. Most of these women had a history of recent antibiotic use. 
Cesarean section may be a particular risk for CDI that develops in the postpartum 
period (Unger et al. 2011, Venugopal et al. 2011).  
inflammatory bowel disease (iBd)
Similar to rising rates of CDI in the general population, patients with IBD (Crohn’s 
disease and ulcerative colitis) have an increased incidence of CDI (Rodemann et al. 
2007). In one study the majority of patients with IBD acquired CDI as outpatients 
(76 %) (Issa et al. 2008). CDI patients with IBD tend to have more severe disease, 
and are more likely to die or to need urgent colectomy than CDI patients who do 
not have underlying IBD (Ananthakrishnan and Binion 2010). Risk factors for CDI 
include severe underlying IBD, ongoing immunosuppression and colonic disease; 
thus rates of CDI are higher in individuals with ulcerative colitis than in those 
with Crohn’s disease (Issa et al. 2008, Rodeman et al. 2007, Jodorkovsky et al. 
2010, Jen et al.2011). Among the different therapies, the highest risk appears to 
be with corticosteroid use, which confer a threefold increase of CDI. Corticosteroid 
exposure within 2 weeks of the diagnosis of CDI was also associated with a twofold 
increase in mortality (Das et al. 2010).
The clinical presentation of CDI and flare of  IBD may be similar and requires a 
high index of suspicion for prompt detection and institution of appropriate therapy. 
Up to 20% of IBD flares are associated with a positive C. difficile stool result (Meyer 
et al.2004), suggesting that CDI may not only mimic but can also precipitate an IBD 
flare. The American College of Gastroenterology (ACG) 2013 guidelines (Surawicz 
et al. 2013) recommend  that all patients who require hospitalization because of 
an IBD flare, as well as ambulatory patients with risk factors for CDI (e.g., recent 
hospitalization, antibiotic use) or unexplained worsening of symptoms in the 
setting of previously quiescent disease, should be tested for C. difficile. The same 
guidelines recommend also ongoing immunosuppression be continued at existing 
doses in IBD-CDI patients. Escalation of the corticosteroid dose or initiation of anti-
TNF (anti-tumour necrosis factor) therapy in patients with a positive CDI probably 
should be avoided for 72 hours after initiating therapy for CDI.
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2.4 PAthOgenIC feAtuReS Of C. DIffICILe 
2.4.1 PAthOgeneSIS
C. difficile is an anaerobic, gram-positive, spore forming bacillus that is acquired 
via the fecal-oral route. C. difficile spores are the transmissible form, contribute to 
survival of the organism in the host, and are responsible for recurrence of disease 
when therapy is ceased. Like other bacterial spores, they are metabolically dormant 
and are resistant to desiccation, chemicals and extreme temperatures. Spores 
frequently contaminate the environment around patients with CDI, potentially 
persisting for months and even years. Although colonization of healthy non 
hospitalized adults is uncommon (i.e., rate <5%), colonization among hospitalized 
patients and especially nursing home residents may range from 25% to 55% (Clabots 
et al 1992, Riggs et al 2007). Transmission in health-care facilities results mostly 
from environmental surface contamination and hand carriage by staff members and 
infected patients. Whereas vegetative cells are killed in the acidic environment of the 
stomach, acid resistant spores pass through relatively undamaged and convert to 
vegetative forms in the small bowel after exposure to primary bile acid (Wilson 1993).
Perturbation of the normal bowel microflora, most often from antibiotic use, 
leads to the loss of colonization resistance. In this setting C. difficile endogenous or 
exogenous spores germinate and vegetative cells multiply. The organism adheres to 
the mucus layer by means of its multiple adhesins and penetrates the mucus with 
aid of flagella and proteases. Once it penetrates mucus, the organism adheres to 
enterocytes and colonization begins. 
Only toxigenic strains are associated with the development of C. difficile diarrhea. 
In summary the pathogenesis of CDI consist of alteration of the normal fecal flora, 
colonization with toxigenic C. difficile and growth of the organism with elaboration 
of its toxins 
2.4.2 vIRuLenCe fACtORS
Toxins
The main C. difficile virulence factors are the two large clostridial toxins, toxin A 
and toxin B. Toxin A and toxin B are encoded on the pathogenicity locus(PaLoc), 
which comprises five genes, tcdA, tcdB, tcdC, tcdR, and tcdE. Toxin A and toxin 
B are encoded by the genes tcdA and tcdB. TcdR gene and tcdC gene encode 
proteins involved in regulating the expression of toxin A and toxin B. The product 
of tcdE is postulated to facilitate the secretion of the toxins from the cell. The 
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DNA sequence of the Paloc is variable, and strains with changes in this region are 
defined as different toxinotypes (Rupnik 2008). Nontoxigenic strains lack the PaLoc. 
Some strains produce a third toxin known as binary toxin or C. difficile transferase 
(CDT). The clinical significance of binary toxin in CDI remains uncertain. It is found 
in approximately 6%– 12.5% of strains overall (Carroll et al 2012). In a recent study 
patients with binary toxin had a higher 30-day case-fatality rates than patients 
without binary toxin, irrespective of PCR ribotype (Bacci et al 2011). 
Sporulation and germination
It has also been postulated that increased sporulation may be associated with 
hypervirulence ( Merrigan et al 2010, Dawson et al 2011) although this also remains 
controversial, particularly as in vitro experiments may not reflect in vivo behaviour. 
There is no simple relationship between antibiotic mediated depletion of the colonic 
microbiota and the induction of C. difficile spore germination with subsequent 
toxin production. Rather, antibiotic exposure might directly stimulate germination 
of spores and toxin production (Saxton et al 2009). The bacteriological response 
to vancomycin varies among strains and possibly correlates with the germination 
capacity (Baines et al 2008). Further investigation of the factors that affect both 
sporulation and germination could provide insights into the risk factors and 
treatment options for CDI.
Surface layer proteins and adherence
Surface proteins are integral to the adherence of the organism to the gut mucosa 
and can induce both inflammatory and antibody responses in the host (Calabi et 
al. 2002, Drudy et al 2004, Wright et al. 2005, Péchiné et al. 2005, Ausiello et al. 
2006). There is considerable variability between the surface proteins of different 
strains. The precise role of  these factors in the virulence of C. difficile is unclear. 
These surface-exposed proteins are potential candidates for vaccine targets and 
novel diagnostic tests.
Toxin variant strains, ribotype 027
Toxinotype  refers to a particular strain of C. difficile based on polymerase chain 
reaction (PCR)-restriction fragment analysis of the PaLoc. All strains in a given 
toxinotype have identical changes in the PaLoc.
The variant toxin genes encode variant toxins with alterations in their substrate 
specifity or can even result in the absence of one or both toxins. In addition to 
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changes in tcdA and tcdB, changes in the other genes of the PaLoc may also alter 
virulence. Currently there are over 30 known toxinotypes (Carter et al. 2012).
It was initially believed that toxin A was the most important toxin in CDI, but 
recently the importance of toxin B has been re-stated. Most disease is caused by 
strains that produce both toxins, but 2% to 5% of disease is the result of only toxin 
B (Digg and Surawicz 2009). TcdA−TcdB+ strains can cause the entire spectrum 
of symptoms of CDI. Toxin B may also have the capacity to cause systemic damage 
to the host in addition to localised damage within the gut (Hamm et al. 2006). 
Multiple organ failure encountered with small percentage of patients may be a 
result of systemic toxin damage (Dobson et al 2003).
At the clinical level, given toxinotypes can be linked to specific disease 
characteristics or patient populations in epidemic settings, but in general, 
toxinotype is not predictive of clinical disease expression. It is likely that multiple 
factors determine whether a strain is virulent and/or epidemic. Hypervirulent 
refers to toxin variant strains of C. difficile that are associated with increased toxin 
production and severe clinical disease.
Many epidemics of CDI are caused by a novel strain, ribotype 027, which 
has unique characteristics that may explain the virulence. This strain produces a 
binary toxin and has a partial deletion in a toxin regulator gene (tcdC) that cause 
hyperproduction of toxins A and B in vitro (Akerlund et al. 2008, Warny et al. 
2005). Aside from having altered TcdC, epidemic 027 strains have five unique 
genetic regions not present in historical 027 strains (Stabler et al. 2006). These 
genes include mutations that explain enhanced toxicity, motility, survival and 
increased sporulation. Also unlike historic isolates, epidemic isolates of C difficile 
ribotype 027 were resistant to fluoroquinolones (McDonald et al. 2005, Loo et al. 
2005), which suggests that the increased use of quinolones may have influenced 
the emergence of this strain. Compared with other strains, ribotype 027 has a 
higher infection-to-colonization ratio (Loo et al. 2011) and it has been associated 
with a poorer response to therapy and higher recurrence rate (Huttunen et al. 
2012), an effect observed across treatment types and despite lack of demonstrable 
resistance in vitro (Petrella et al. 2012).  
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2.5 RISk fACtORS Of CDI
2.5.1 RISk fACtORS fOR DISeASe
The most common risk factor for the development of CDI is recent or current 
antibiotic use, which leads to alteration in bowel microflora and the loss of 
colonization resistance. Other important risk factors include age greater than 65 
years, multiple underlying comorbidities and hospitalization (McFarland 1998, 
Pepin et al. 2005²).
Almost all antimicrobial agents except for aminoglycosides have been associated 
with development of CDI (Suneshine and McDonald 2006). The risk is increased 
if C. difficile is resistant to the antimicrobial agents used (Johnson et al. 1999). 
Alternatively, antimicrobials that are active against C. difficile decrease the risk of 
colonization and infection during their use (Donskey 2004, Gerding 2004). The 
antibiotic susceptibility of C. difficile strains, including epidemic clones, is changing 
and it also varies widely between countries (Huangh et al. 2010). Even very limited 
exposure, such as single-dose surgical antibiotic prophylaxis, increases a patient’s 
risk of both C. difficile colonization (Privitera et al. 1991) and symptomatic disease 
(Yee et al. 1991). In studies that evaluate risk for CDI after the use of an individual 
antimicrobial, treatment with multiple antimicrobials can lead to controversial 
results, making determination of risk inherently more difficult (Wilcox 2001). 
Therefore, it is difficult to assess the independent role of each antimicrobial to the 
risk of developing CDI. In general the number of administered antibiotics, their 
dosage and the duration of therapy have been identified as factors determining the 
risk for CDI (Owens et al. 2008, Dubberke et al. 2007, Wiström et al. 2001). CDI risk 
is elevated 7- to 10- fold during antibiotic therapy and the first month after cessation 
of antibiotics. It remains elevated for at least 3 months after administration of 
antibiotics (Hensgens et al. 2012¹). 
The highest risk of developing CDI has been associated with use of clindamycin, 
cephalosporins, and fluoroquinolones (Table 3). At the moment, cephalosporins are 
the leading antimicrobial class associated with CDI (Muto et al. 2007, McCusker et 
al 2003, Loo et al. 2011, Owens et al. 2007). C. difficile isolates are fully resistant 
to most cephalosporins (Gerding 2004, Johnson et al.1999). The emergence and 
spread of C. difficile 027 correlates with acquired resistance to the fluoroquinolones, 
a trait that was not present in historic strains of the same genotype (Pepin et 
al. 2005², Muto et al. 2005, McCusker et al. 2003). Historically most of the 
prevalent types in human populations were clindamycin resistant (Labbe et al. 
2008, Johnson et al. 1999). At the moment, C. difficile resistance for clindamycin 
is variable (Johnson et al. 2009). Clindamycin’s relatively unique preference for 
impacting the intestinal flora over a prolonged period may increase the window 
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of susceptibility to CDI to a time point after the antimicrobial is discontinued 
(Sambol et al. 2002, Larson and Borriello 1990). 
table 2  Antimicrobial Agents Associated with CDI (those available in Finland).
most frequently less frequently rarely or never
Ampicillin and amoxicillin Carbapenems Daptomycin
Cephalosporins Other penicillins Metronidazole 
Clindamycin Trimethoprim/sulfamethoxazole Parenteral aminoglycosides
Fluoroquinolones Rifampicin
Tetracyclines, Tigecycline
Vancomycin
Adapted from Higa and Kelly 2013 and Brown et al. 2013
There have been some recent reports of patients with community-onset CDI 
who had not been exposed to antibiotics. However, these cases are infrequent 
compared with the number of patients with CDI in hospital who have been exposed 
to an antibiotic in the 2–3 months before infection (Dial et al. 2008). Risk factors in 
the community are likely to be different. These may include genetically determined 
differences in immune reactivity and inherent differences in the ability of a specific 
individuals intestinal microbiome (Arungam et al. 2011) to resist colonization by 
C. difficile .
As a lower acidity environment allows vegetative forms of C. difficile to 
survive, emerging data indicate the need to avoid unnecessary use of gastric acid 
antisecretory medications. Two recent meta-analyses confirm association and 
strengthen the evidence that proton-pump inhibitor use is associated with an 
increased risk of CDI (Janarthanan et al 2012, Kwok et al 2012). 
In addition, host factors play a role in the CDI development (Johnson et al. 
2009, Gould and McDonald 2008). Colonization with C. difficile and high levels 
of serum IgG against C. difficile toxin A appear to provide protection against CDI 
(Shim et al. 1998, Kyne et al. 2000). Thus, the inability to mount an appropriate 
immune response in patients on chemotherapy or with severe underlying illness 
may explain the increased risk in these populations. Other important host factors are 
IBD (Rodeman et al. 2007, Issa, et al. 2008), use of feeding tubes or gastrointestinal 
surgery (McFarland et al. 1998, Bartlett et al. 1990). Variability in host factors may 
explain the wide spectrum of symptoms and course of disease.
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2.5.2 RISk fACtORS fOR ReCuRRent CDI
The risk factors for RCDI are slightly different from those for initial CDI. Two 
likely mechanistic factors increasing the risk of RCDI are an inadequate immune 
response to C. difficile toxins (Kyne et al. 2001) and decreased overall diversity of 
the gut microbiota (Chang et al. 2008). Important epidemiologic risk factors include 
advanced age over 65 years (Pepin et al. 2005¹, Bauer et al. 2011), continuation 
of other antibiotics, and prolonged hospital stays (Johnson et al. 2009, Pepin et al 
2005¹, Eyre et al 2012). Infection with the 027 strain of C. difficile may also convey 
an increased risk of recurrence (Petrella et al. 2012), although this has not been 
confirmed in all recent analyses of risk factors for CDI recurrence (Eyre et al. 2012).
Patients are also at increased risk of recurrent CDI if they have severe or 
extremely severe underlying disease, as indicated by a modified Horn index (Table 
3) score of 3 or 4 (Hu et al. 2009). In a recent study lymphopenia at the end of 
CDI treatment appeared to be a marker for CDI recurrence (Lavergne et al 2013). 
Once patients have experienced one recurrence of CDI, they are at significantly 
increased risk of further recurrences (Bauer et al. 2011). Also antibiotics used 
in C. difficile treatment alter the colonic microflora and therefore predispose to 
recurrence. The risk of recurrence more than doubles after two or more recurrences 
(McFarland 1998). Specific comorbidities that have been found to be associated 
with an increased risk of recurrent CDI include a compromised immune system 
(Cohen 2009), renal impairment (Do et al 1998) and inflammatory bowel disease 
(Kelsen et al. 2011). 
Prominent risk factors have been examined to develop and validate a clinical 
prediction tool for recurrent CDI, with three factors (age >65 years, severe underlying 
disease (by the Horn index score, Table 3), and continued use of antibiotics for 
non-CDI infections) being highly predictive of CDI recurrence (Kelly 2013). Each 
predictor—age over 65 years, Horn index 3-4, and additional antibiotic use—was 
assigned 1 point. Patients with scores 2 or 3 were classified as high risk. The clinical 
prediction rule effectively discriminated between patients with and without recurrent 
CDI, with 77 % accuracy (Hu et al. 2009).
table 3  Horns index of disease severity
score
Single mild illness 1
More severe illness but uncomplicated recovery expected 2
Major illness or complications or multiple conditions requiring treatment 3
Catastrophic illness that may lead to death 4
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2.5.3 RISk fACtORS fOR ADveRSe OutCOme
Of several clinical factors which have been linked to CDI of increased severity, and 
to adverse clinical sequelae, older age again has emerged as an important risk 
factor (Loo et al. 2011, Cohen et al. 2010). Factors that are strongly suggestive of 
severe CDI include an elevated peripheral white blood cell count (>15x109/l), with 
counts above 50x109/l being considered a warning of likely death (Lamontagne et 
al. 2007) and a rising serum creatinine level (Pepin et al.2005³). Leukocytosis likely 
reflects the severity of colonic inflammation. An elevated serum creatinine level 
may indicate severe diarrhea with subsequent dehydration or inadequate renal 
perfusion (Loo et al. 2011). In addition pre-existing corticosteroid use is a potentially 
useful risk markers for mortality in CDI (Bloomfield et al. 2012). Fever, haematocrit, 
diarrhoea severity and several comorbidities were not associated with mortality in 
the meta-analysis, raising questions about their inclusion in CDI severity scores.
The role of particular ribotypes in the clinical outcome of CDI is complex 
(Bloomfield et al. 2012). C. difficile 027 has been suggested to cause a more severe 
disease than other ribotypes (Warny et al. 2005). However, recent report suggest 
that ribotypes 027 or 078 are not independent predictors of severe outcome when 
adjusted by the patient’s leukocyte count and albumin level (Walk et al. 2012).  
2.6 CliniCal features of Cdi 
The most common clinical presentation of CDI is diarrhea associated with a 
history of antibiotic use. Factors other than antimicrobial use that can predispose 
to CDI include bowel ischemia, recent bowel surgery, uremia, malnutrition and 
chemotherapy. The incubation period from ingestion of C. difficile to onset of 
symptoms has been estimated to be a median of 2–3 days (McFarland et al 1989, 
Johnson et al 1990, Samore et al 1994). In some patients, no recent antibiotic use 
or health care exposures are identified. Colonization and infection with toxigenic 
strains can lead to a spectrum of illness including asymptomatic carriage, or mild 
diarrhea, which resolves with discontinuation of antibiotics, to fulminant colitis, 
which has high mortality. The onset of diarrhea is typically during or shortly after 
receipt of a course of antibiotic therapy but may occur from a few days after the 
initiation of antibiotic therapy to as long as 8 weeks after the termination of therapy 
(Mogg et al. 1979).
In some patients disease is localized to the proximal colon. These patients may 
present with an acute abdomen, localized rebound tenderness and no diarrhea. 
Considering this diagnosis in such a patient with subsequent confirmation based on 
stool studies and computed tomography (CT) may help avoid unnecessary surgery 
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(Drapkin et al. 1985). Overall, fever occurs in 28% of cases, leukocytosis in 50%, 
and abdominal pain in 22% (Bartlett et al. 1980). 
2.6.1 ASymPtOmAtIC CARRIAge
Carriage of C. difficile occurs in 5 – 15 % of healthy adults and may be transient 
(Ozaki, et all. 2005, Matsuki et al.2005, Nakamura et al. 1981). Among the elderly, 
carriage rates may be higher especially in those in long-term care or nursing home 
facility. Several studies have alluded to the importance of asymptomatic C. difficile 
carriers as a potential source of transmission (Riggs et al. 2007, Sethi et al. 2010, 
Johnson et al.1990). In a study of elderly patients in a long-term care facility affected 
by an outbreak of CDI, asymptomatic carriers outnumbered symptomatic patients 
by seven to one (Sethi et al 2010). However, levels of C. difficile contamination 
on the skin and in the surrounding environment of carriers approached those for 
symptomatic patients, suggesting that the former may be an important source of 
onward transmission (Sethi et al. 2010). In this respect, it is noteworthy that many 
CDI patients in whom diarrhoea resolves following a course of specific antibiotic 
therapy become asymptomatic carriers, and may continue shedding C. difficile 
spores for several weeks after treatment has ended.
2.6.2 mILD tO mODeRAte CDI
Mild disease consists of mild to moderate nonbloody diarrhea with minimal 
systemic symptoms and a normal physical examination. Diarrhea is usually the 
only symptom, with patients experiencing up to but usually considerably less than 
10 bowel movements per day (Bartlett 2002). Stools are usually watery, with a 
characteristic foul odour, although mucous or soft stools also occur. Patients can 
also present with symptoms of colitis: fever and lower abdominal cramps. 
2.6.3 SeveRe CDI
Around 10% of cases of CDI have clinical features consistent with severe CDI 
(Muto et al 2005). There is no universally agreed upon definition for severe CDI. 
The Society for Healthcare Epidemiology of America/Infectious Diseases Society 
of America (SHEA/IDSA) guidelines define severe CDI on the basis of WBC 
greater than 15,000/L or a level of creatinine 1.5-fold above the patient’s baseline 
value (Cohen et al 2010). Severe disease is characterized by profuse, usually non 
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bloody, diarrhea, abdominal pain, fever, nausea, anorexia, malaise, and abdominal 
tenderness. C-reactive protein and leukocytes can be moderately or even highly 
elevated, and a leukemoid reaction is not a rarity. In  one study 58 % of the patients 
with unexplained leukocytosis had CDI (Wanahita et al 2003). Hypoalbuminemia 
is also a common feature because CDI is a protein-losing enteropathy and low 
albumin is considered a marker of inflammatory states.
2.6.4 fuLmInAnt CDI
Fulminant colitis occurs among 1%–3% of patients and is characterized by signs and 
symptoms of severe toxicity with fever, and diffuse abdominal pain and distension 
(Triadafilopoulos and Hallstone 1991, Rubin et al. 1995, Kelly et al. 1994). The 
timing from onset of any CDI symptoms to fulminate colitis varies from weeks 
to just a couple of hours; patients with rapid progression have worse outcomes.
(Dallal et al. 2002). Although profuse diarrhea may be present,  patients with severe 
pseudomembranous colitis may have little to no diarrhea if they have an associated 
paralytic ileus or toxic megacolon (Kelly and LaMont 1998). Complications 
include colonic perforation and peritonitis. Abdominal images show air if colonic 
perforation has occurred and diffuse colonic inflammation. Colonoscopy reveals 
diffuse inflammation and possibly pseudomembranes. Pseudomembranes can 
exist throughout the entire colon, but they are usually most pronounced in the 
rectosigmoid colon.  
Patients with a WBC of greater than 50x109 /l or level of lactate greater than 5 
mmol/L have a poor prognosis (Lamontagne et al 2007). Mortality associated with 
toxic megacolon is high, ranging from 24% to 38%.( Dobson et al.2003, Lipsett et 
al. 1994, Morris et al. 1990).
2.6.5 ReCuRRent CDI
Recurrent disease is defined as symptomatic CDI that recurs after completion of 
an appropriate course of antibiotics for the initial infection. Recurrence can be due 
to either relapse of infection caused by the original strain or re-infection caused by 
a different strain (Barbut et al. 2000, Johnson et al. 1989). In clinical practice, it 
is impossible to distinguish these mechanisms of recurrences. Lack of restoration 
of enteric microbiota, persistence of C. difficile spores within the gut and failure of 
the host to establish an adequate immune response to C. difficile toxins A and B 
(Johnson et al. 1989, Chang et al. 2008, Kyne et al. 2001) appear to all be related 
with the chance of recurrence.
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Clinical severity and outcomes do not change significantly between primary 
infection and recurrences (Louie et al 2011). Recurrence typically happens within 
14 days after cessation of antibiotic treatment for the initial episode; however, it can 
occur for up to 12 weeks after stopping antibiotics (Kelly 2009). The overall risk of 
RCDI has been reported as 10-20% after initial CDI (Surawicz et al. 2013), 45% after 
a first relapse, and greater than 60% for those with 2 or more recurrences (Bartlett 
1990). Persisting diarrhea after resolution of CDI may not be caused by a recurrence 
but instead may reflect simple AAD or be a form of postinfectious irritable bowel 
syndrome (IBS). In one recent study persistent diarrhea in CDI correlated with 
intestinal inflammation markers and not fecal CDI burden (El Feghaly et al. 2013).
2.6.6 DIffeRentIAL DIAgnOSIS Of CDI
None of these clinical features are specific to CDI, and a variety of disorders 
may cause similar clinical presentations. These include diarrhea caused by other 
enteric pathogens, AAD, inflammatory bowel disease, adverse reactions to other 
medications, ischemic colitis and intra-abdominal sepsis. The presence of fever 
and leukocytosis favour C. difficile or other infectious etiology. Postinfectious IBS 
occurs in about 10 % of patients after successful CDI treatment (Kelly 2009). These 
patients may have watery diarrhoea mimicking CDI.
Antibiotic-associated haemorrhagic colitis (AAHC) is an uncommon cause 
of bloody diarrhoea in patients taking penicillin or penicillin-related antibiotics. 
(Moulis and Vender 1994, Toffler et al. 1978, de Mulder 1978, Barrison and Kane 
1978). It has also been reported after antibiotic therapy with quinolones and 
cephalosporins (Koga et al. 1999). The accumulated evidence implicates Klebsiella 
oxytoca as a probable cause of AAHC ( Beaugerie et al 2003, Benoit et al. 1992, 
Högenauer et al. 2006). Some K. oxytoca strains isolated from patients with AAHC 
produce a cytotoxin that can induce epithelial cell death and may predispose certain 
patients to hemorrhagic colitis during exposure to antibiotics. K oxytoca also 
produces a chromosomally encoded beta-lactamase that renders it resistant to 
aminopenicillins. Therapy with these antibiotics and others to which K oxytoca is 
resistant presumably contributes to its overgrowth and the development of AAHC. 
Other possible mechanisms for AAHC include allergic reaction (Toffler et al. 1978) 
and mucosal ischemia (Yonei et al. 1996).
Characteristically, the symptoms of AAHC begin within 2-7 days of antibiotic 
use. Patients develop sudden onset of lower abdominal pain and loose, watery 
stools, followed within 6 hours by rectal blood loss (Moulis and Vender 1994). 
Its rapid resolution after cessation of antibiotics (Sakurai et al. 1994) and its 
predilection for the right side of the colon (Iida et al. 1985) may result in the 
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diagnosis being missed if a full colonoscopy is not performed within days of the 
onset of symptoms. The key macroscopic feature is segmental distribution of 
mucosal hemorrhage and mucosal edema localized predominantly in the right 
colon, with lack of pseudomembranes.
2.6.7 extRAInteStInAL CDI
Extraintestinal manifestations of CDI are unusual. There are case reports of rare 
presentations of CDI, including patients with bacteremia, intra-abdominal and 
perianal abscesses, peritonitis, wound and joint infections (Feldman et al. 1995, Byl 
et al. 1996, Wolf at al. 1998, Deptula et al 2009). Extraintestinal infections with C. 
difficile are often polymicrobial and identified among patients with underlying 
comorbid conditions (Wolf et al 1998).
Reactive or postinfectious syndromes can occur after CDI, including reactive 
arthritis and IBS (Birnbaum et al 2008, Sethi et al 2011). As with other reactive 
arthritides after enteric infections, many of these patients are positive for the 
HLA-B27 (Atkinson and McLeod 1998, Hayward et al 1990). 
2.7 DIAgnOSIS Of CDI
2.7.1 LAbORAtORy DIAgnOSIS
The best standard laboratory test for diagnosis has not been clearly established. 
For the past 30 years, the two primary reference tests are the C. difficile cytotoxin 
neutralization assay (CCNA) and toxigenic culture (TC) ( Planche and Wilcox 2011, 
Sambol et al. 2000). The first detects the presence of C. difficile toxins, toxin B 
and toxin A, in a fecal sample. By contrast, TC detects C. difficile strains that have 
the capacity to produce toxins. C. difficile culture alone is not sufficient because 
not all C. difficile strains produce toxin (Rea et al. 2012, Viscidi et al. 1981). The 
enzyme immunoassay (EIA) for detection of toxins A and B has been the most 
widely used diagnostic test for CDI because of its rapid turnaround, low cost, and 
simplicity. However, EIAs for toxins A and B are known to have low sensitivity 
(60%–80%) compared with TC (Eastwood et al 2009). Different strains of C. 
difficile can provide different results in toxin EIA assays (Tenover et al 2010).
C. difficile nucleic acid amplification test identifies genes (not the toxin) that 
encode the toxins (usually toxin B) by using PCR or loop-mediated isothermal 
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amplification of DNA. These assays have a short turnaround time, and their 
sensitivities range from 84% to 94% compared with toxigenic stool culture, making 
their use by clinical laboratories very attractive (Deshpande et al 2011). The use 
of more sensitive and rapid testing for CDI diagnosis may lead to treatment of 
patients before they progress to severe CDI. However, healthcare facilities should 
expect an increase in CDI rates when transitioning to a PCR-based assay and also 
should emphasize appropriate testing practices to avoid detection of asymptomatic 
carriers. As diarrhea is a common symptom in the hospitalized, elderly or long term 
care facility patient, it remains difficult to distinguish the patient with CDI from the 
patient for whom a positive C. difficile test is related to underlying colonization. 
Finally, all laboratory tests must be interpreted in the context of patient symptoms 
and risk factors for CDI.
Only stools from patients with diarrhea should be tested for C. difficile.(Cohen et 
al. 2010). Very occasionally, a patient with ileus and complicated disease will have 
a formed stool. Rectal swabs can be used for PCR and thus may be useful in timely 
diagnosis of patients with ileus (Kundrapu et al 2012). Several studies have shown 
that repeat testing after a negative test is positive in < 5 % of specimens and repeat 
testing increases the likelihood of false positives (Debast et al. 2008, Deshpande et 
al. 2010, Luo and Banei 2010). If repeat testing is requested, the physician should 
confer with the laboratory to explain the clinical rationale. Both toxin A + B EIA 
and TC may remain positive for a long as 30 days in patients who have resolution 
of symptoms (Surawicz et al. 2000, Wenisch et al. 1996). False positive “ test of 
cure ” specimens may complicate clinical care and result in additional courses of 
inappropriate anti- C. difficile therapy.
2.7.2 ROLe Of enDOSCOPy AnD RADIOLOgy
C. difficile most often causes a nonspecific colitis. However, especially in more severe 
cases, one may see the distinct macroscopic appearance of pseudomembranous 
colitis at endoscopy or by histopathologic examination. At least 90 % of patients 
with pseudomembranous colitis demonstrate either C. difficile or its toxins in stool 
samples (Wolfhagen et al. 1994). Many milder cases only reveal the nonspecific 
findings of erythema and edema. Notably, patients with IBD may not exhibit 
pseudomembranes or classic histologic findings at all  (Issa et al 2008). Endoscopy 
provides the added benefit of aiding in the identification of other causes of diarrhea, 
such as such as cytomegalovirus colitis, graft-versushost disease or, in the case of 
bloody diarrhea, ischemic colitis or IBD.
Computed tomography (CT) scan is normally not required for diagnosing 
CDI, especially for mild-to-moderate disease, but it can be useful for recognizing 
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more severe forms. Colonic inflammation can also be shown on CT as increased 
thickening of colonic wall (Ash et al 2006) with trapping of contrast material, 
pancolitis, pericolonic fat changes and ascites
2.8 tReAtment Of CDI
For 30 years, metronidazole and oral vancomycin have been the main antimicrobial 
agents used in the treatment of CDI. On the basis of two randomized controlled trials 
with oral vancomycin, the FDA and EMEA (European Medicine Agency) granted 
approval for a new macrocyclic antibiotic, fidaxomicin in 2011 (Louie et al. 2011, 
Cornely et al. 2012). In addition to antimicrobials, the prevention and treatment of 
CDI may include infection control measures, antimicrobial stewardship, restoration 
of the protective microbiota, and increased immunity to C. difficile toxins. 
The first step in treatment is cessation of the inciting antibiotics, if this is 
deemed to be medically appropriate. Withdrawing the offending antibiotic will 
lead to resolution of CDI within 48 hours in up to 20% of the cases (Teasley et 
al. 1983). Treatment for CDI can be initiated before laboratory confirmation for 
patients with a high pre-test suspicion of disease. There is no basis for prophylactic 
antibiotics for patients at risk of CDI or asymptomatic colonization with C. difficile 
(Dubberke et al. 2008).
When administered orally, metronidazole is absorbed rapidly and almost 
completely in the small intestine and then excreted again in the bile and in the 
inflamed colon (Bolton and Culshaw 1986). Metronidazole is not present in stool 
samples of asymptomatic patients (Johnson et al. 1992). There may be low levels 
measured in the presence of diarrhea, but concentrations decrease rapidly after 
treatment of CDI is initiated. The activity of  metronidazole against CDI depends on 
back diffusion from the serum across the colonic mucosa, but this is quite fluctuating 
(Bolton and Culshaw 1986). Given the relatively low fecal concentrations achieved 
with metronidazole, even a modest decrease in susceptibility might have a marked 
effect on treatment efficacy in CDI. Previous reports have uniformly demonstrated 
that metronidazole has very good in vitro activity against C. difficile (Shuttleworth 
et al. 1980). In one recent study  minimum inhibitory concentration (MIC) obtained 
by Etest were lower compared with those obtained by agar dilution method (ADM) 
and agar incorporation method (AIM), causing discrepancies in the categorization 
(as susceptible or having reduced susceptibility) of some strains (Moura et al. 2013). 
In another study up to 24.% of the C. difficile ribotype 001 isolates demonstrated 
decreased susceptibility or resistance using the spiral gradient endpoint method and 
the AIM, but not using E-test.(Baines et al. 2008). Even if the significance of both 
in vitro resistance and heteroresistance (Pelaez et al. 2008) to metronidazole in the 
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treatment of CDI remains unclear, the low fecal concentrations of metronidazole 
suggests that C. difficile subpopulations with reduced susceptibility to this antibiotic 
may be one factor responsible for reduced metronidazole efficacy in vivo. Thus 
far the reduced clinical response to treatment with metronidazole has not been 
attributed to resistance to the drug in C. difficile.
Vancomycin has excellent in vitro activity against C. difficile, with a MIC of 
0.75–2.00 μg/ml required to inhibit 90% of strains (Wong et al. 1999, Marchese 
et al. 2000, Jamal et al. 2002). One study has reported intermediate in vitro 
resistance to vancomycin in 3% of C. difficile isolates, with a MIC of 4–16 μg/
ml required to inhibit the growth of these strains (Pelaez et al. 2002). Unlike 
metronidazole,  vancomycin is poorly absorbed, and fecal concentrations following 
oral administration reach very high levels. Vancomycin levels in the colonic lumen 
are over 100-fold greater than the highest MIC ever measured for a strain of 
C.difficile (Bartlett 2009). So emergence of resistance is likely not a concern. Fecal 
levels achieved are high enough that organisms generally considered to be even 
vancomycin insensitive, such as the gram-negative Bacteroides fragilis group, can 
be affected both in vitro (Finegold et al. 2004) and in vivo (Louie et al. 2009). 
Given its poor absorption, orally administered vancomycin is relatively free of 
systemic toxicity. Since intravenous vancomycin is not able to reach the lumen 
of the colon, it has no role in the therapy of CDI. Emergence of vancomycin-
resistant Enterococcus (VRE) has not been shown to be a valid reason to avoid 
use of vancomycin for treatment of CDI, as both vancomycin and metronidazole 
treatment for CDI have been shown to promote VRE acquisition in prospective 
observational studies (Al-Nassir et al. 2008). 
Early prospective, randomized trials concluded that metronidazole was not 
inferior to vancomycin, with initial cure rates over 90% (Teasley et al. 1983, Wenisch 
et al. 1996). Decreased response rates and slower responses for metronidazole have 
been noted since 2004 (Fernandez et al. 2004, Musher et al. 2005, Pepin et al. 2007, 
Belmares et al. 2007, Lagrotteria et al. 2006). However, a 2007 Cochrane meta-
analysis of 12 randomized trials showed that none of 8 antibiotics was superior in 
terms of outcome, and favored metronidazole as initial therapy for its lower cost and 
similar efficacy (Nelson 2007). In the same year, in a large prospective, randomized 
and blinded study vancomycin was shown to be superior to metronidazole in cases 
of severe CDI (Zar et al. 2007). Again, in 2011 published systematic review of the 
comparative effectiveness of CDI treatments, the three studies directly comparing 
vancomycin and metronidazole failed to show a significant difference between the 
two treatments (Drekonja et al. 2011). Limitations of the available evidence include 
substantial variability among studies, including the definitions used for CDI, initial 
cure and recurrence, and the durations of treatment and follow-up.
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Fidaxomicin has minimum systemic absorption, high faecal concentrations and 
restricted activity against normal gut flora (Louie et al. 2009, Tannock et al. 2010). 
There is no evidence for cross-resistance between fidaxomicin and other classes of 
antibiotics. In vitro frequency of spontaneous mutations has been demonstrated 
to be low. In both published phase 3 trials (Louie et al. 2011, Cornely et al. 2012), 
fidaxomicin demonstrated non-inferiority to vancomycin for clinical response at the 
end of therapy and showed lower rates of relapse when compared to vancomycin 
in patients infected with non 027 C. difficile strains. There are limitations to these 
findings. Neither trial extended to 90 days and there is no biological plausibility to 
explain a strain-specific superiority of fidaxomicin. Additional literature suggests 
that fidaxomicin might have a favourable profile compared with alternate regimens 
when patients require additional concomitant antibiotics (Mullane et al. 2011). More 
study is needed to determine the place of fidaxomicin in treatment of patients with 
severe CDI and patients infected with the 027 strain of C. difficile.
Nitazoxanide, an antimicrobial agent already approved for Giardia and 
Cryptosporidium infections, has been shown to have statistically comparable 
efficacy with metronidazole in a small prospective randomized trial (Musher et 
al. 2009). It may also have a role in cases of CDI nonresponsive to metronidazole, 
although there are mixed data with comparison to vancomycin (Gerding and 
Johnson 2010). Larger studies comparing the efficacy of nitazoxanide with that of 
standard therapies are needed to define its place in the management of CDI and 
to test its noninferiority to currently available agents.
2.8.1 tReAtment Of A fIRSt ePISODe Of CDI
The treatment of CDI is described in Table 4. Treatment of CDI should be based on 
disease severity, although it is difficult to set a rigid set of criteria for the assessment 
of prognosis and severity of CDI. Patients with mild-to-moderate CDI should be 
treated with metronidazole 500 mg orally three times per day for 10 days. Patients 
with severe CDI should be treated with vancomycin 125 mg orally four times per day 
for 10 days. The assessment of disease severity can be made by evaluating clinical 
characteristics including fever, age, ICU admission, elevated WBC or creatinine, or 
low albumin (Zar et al. 2007).
Failure to respond to metronidazole therapy within 5-7 days should prompt 
consideration of a change in therapy to vancomycin at standard dosing. (Musher 
et al. 2005, Surawicz et al. 2013). The time to resolution of diarrhea might be 
shorter with vancomycin than with metronidazole therapy (Belmares et al. 2007). 
Prospective trials have not compared regimens with durations longer than 10 days. 
There is no evidence to support administration of combination therapy to patients 
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with uncomplicated CDI. The use of anti-peristaltic agents to control diarrhea 
from confirmed or suspected CDI should be limited or avoided, with concern for 
minimizing impaired toxin clearance and precipitate complicated disease (Koo et 
al. 2009, Kato et al. 2008). 
In patients who are allergic or intolerant (e.g. nausea, vomiting, and taste 
disturbances) to metronidazole and for pregnant / breastfeeding women, vancomycin 
should be used. First trimester exposure to metronidazole is not recommended in 
FDA guidelines because of concern regarding ready placental transmission and 
possible facial anomalies following exposure (Surawicz et al. 2013).
table 4  Treatment of CDI
Asymptomatic carrier No treatment required
Initial CDI Oral metronidazole 400mg t.i.d for 10 days
Severe CDI Oral vancomycin 125mg four times a day for 10 days
Complicated CDI Intravenous metronidazole 500mg t.i.d. and oral vancomycin 500 mg 
four times a day
1 st recurrence of CDI Oral metronidazole 400mg t.i.d or oral vancomycin 125mg four times 
a day for 10 days
2  st recurrence of CDI Vancomycin 125mg four times a day for 7 days and then tapering 
doses
3 st recurrence of CDI FMT or oral fidaxomicin 200mg twice a day for 10 days or oral 
rifaximin 200mg four times a day for 10 days
Modified by Surawicz et al. 2013 
2.8.2 tReAtment Of SeveRe, COmPLICAteD CDI
Severe complicated or fulminant CDI denotes progression to a complication 
like megacolon, ileus, or other sign of severe systemic involvement, including 
hypotension or any evidence of end organ failure and metabolic derangements 
including lactic acidosis (Higa and Kelly 2013). Symptoms of ileus include acute 
nausea, emesis, sudden cessation of diarrhea, abdominal distension, while 
radiological signs are consistent with disturbed intestinal transit. First-line 
therapy is oral vancomycin at a dose of 500 mg every 6 hours for 10 to 14 days, 
with the addition of intravenous metronidazole 500 mg every 6 hours. Direct 
instillation of vancomycin via colonic retention enema, colonoscopy, or long 
rectal tube is recommended if ileus is present (Shen and Surawicz 2008). For 
this approach, vancomycin 500 mg in a volume of at least 500 ml four times per 
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day is recommended (Olson et al. 2004, Pasic et al. 1993, Apisarnthanarak et 
al. 2002). Use of high doses of colonic administration of vancomycin is safe, but 
high serum concentrations have been noted with long courses of 2 g per day, with 
renal failure. It would be appropriate to obtain trough serum concentrations in this 
circumstance. The use of empiric antibiotics (other than those used to treat CDI) 
should be minimized and limited to situations where there is a clear indication 
(Higa and Kelly 2013).
Passive immunotherapy with intravenous immunoglobulins  has been used for 
some patients not responding to other therapies (McPherson et al 2006) but no 
controlled trials have been performed. Case reports have suggested that tigecycline 
may be successful for treatment of severe or severe complicated CDI, when prior 
therapy has failed (El-Herte et al. 2012, Herpers et al. 2009, Lu et al. 2010). 
Tigecycline is a derivative of minocycline and it is administered intravenously. 
Tigecycline achieves fecal concentrations well above the MIC for C. difficile, because 
of primary biliary excretion of unchanged drug.
2.8.3 SuRgeRy fOR COmPLICAteD CDI
Emergent colectomy can be life saving in severe disease. No randomized trials 
exist of surgical management of fulminant CDI. Indications for colectomy include 
toxic megacolon, perforation, peritonitis, severe complicated disease including 
shock/organ failure, and disease persistence or progression despite appropriate 
medical therapy (Lamontagne et al 2007). Currently, there is no scoring system 
that creates a threshold for operative management. ACG guidelines recommend 
consideration of surgical therapy in patients with any one of the following attributed 
to CDI: hypotension requiring vasopressor therapy; clinical signs of sepsis and 
organ dysfunction; mental status changes; WBC count ≥ 50,000 cells/ μ l, lactate 
≥ 5 mmol / l; or complicated CDI with failure to improve on medical therapy after 
5 days (Surawicz et al. 2013). Fulminant CDI was indication for every third of 
colectomies in a Finnish tertiary-level mixed intensive care unit (Sipola et al. 2013). 
The standard surgical approach is to perform a total colectomy with preservation 
of the rectum and a temporary end ileostomy. However, one recent case-controlled 
study treated patients with severe, complicated disease with loop ileostomy (Neal et 
al. 2011). Survival of patients compared with historical controls who had undergone 
colectomy improved (19 % vs. 50 %)  with this new treatment. Other advantages are 
the potential preservation of the colon and fewer long-term adverse consequences.
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2.8.4 tReAtment Of ReCuRRent CDI
Management of RCDI is poorly studied, and the recently published clinical practice 
guidelines give recommendations for RCDI that are based on relatively poor quality 
of evidence (Cohen et al. 2010, Surawicz et al. 2013, Bauer et al. 2009). RCDI is a 
therapeutic challenge because there is no uniformly effective therapy. Treatment of 
a first recurrence of CDI depends on the presentation at the time of recurrence and 
is stratified depending on disease severity in the same way as was for the treatment 
of an initial episode. Using either metronidazole or vancomycin treatment of a 
first recurrence does not alter the probability of a second recurrence (Pepin et al. 
2006). Positive toxin assay at time of completion of therapy for CDI does not predict 
risk of relapse (Dubberke et al. 2007). Recurrence is not a result of antimicrobial 
resistance to metronidazole or vancomycin but rather an impairment of colonization 
resistance resulting from recent or continued antibiotic use or due to an impaired 
immune response.
In an observational study metronidazole was not inferior to vancomycin for 
treating patients with a first recurrence of CDI (Pepin et al. 2006). Metronidazole 
should not be used beyond the first recurrence or for long-term therapy because of 
peripheral neuropathy and other adverse effects (Kapoor et al. 1999). A substantial 
proportion of patients with a second recurrence will be cured with vancomycin 
with use of a taper and/or pulsed regimen. (McFarland et al. 2002). There are 
no controlled data to support specific tapering or pulse regimens (Tedesco et 
al. 1985). Options for treatment of a second or subsequent recurrence include a 
prolonged, tapering, and then pulsed dose oral vancomycin, oral fidaxomicin, or 
oral vancomycin followed by oral rifaximin (McFarland et al. 2002, Louie et al. 
2011, Garey et al. 2011).
Rifaximin is a poorly absorbed oral rifamycin derivative, which has been 
proposed as a rescue option in the treatment of second and later recurrences. C. 
difficile usually shows good in vitro susceptibility to rifaximin, but MICs may rise 
postexposure which raises concerns of the potential for resistance to develop (Koo 
and DuPont 2010). Data from uncontrolled and relatively small studies suggest that 
rifaximin may have a role in the treatment of patients with multiple recurrences 
or those for whom other treatments have failed  (Johnson et al. 2009, Garey et 
al. 2011).
2.8.5 tReAtment Of thIRD AnD SubSequent ReLAPSeS
In addition to tapered and pulsed vancomycin regimens, other management 
strategies for multiple CDI recurrences that have been reported in uncontrolled 
case series and appear to be useful include standard therapy with probiotics, 
37
standard therapy followed by rifaximin, switching to nitazoxanide, intravenous 
immunoglobulin, and FMT (Johnson 2009). 
2.8.6 feCAL mICRObIOtA tRAnSPLAntAtIOn
FMT is the term used when stool is taken from a healthy individual and instilled 
into a sick person to cure a certain disease (Bakken et al 2011). ACG guidelines 
recommend to consider FMT, if  there is a third recurrence after a pulsed vancomycin 
regimen. An randomized controlled trial of donor feces administered by duodenal 
infusion with gut lavage showed significant efficacy compared to vancomycin or 
vancomycin with gut lavage without donor feces (van Nood et al 2013). The cure 
rate with FMT was 81 % compared to 23 % with vancomycin alone and 31% with 
vancomycin and gut lavage. Considering that disruption of the indigenous fecal 
flora is likely a major risk for infection with C. difficile and, particularly, for RCDI, 
instillation of stool from a healthy donor has been used with a high degree of success 
in several other uncontrolled case series (Kassam et al 2013).
Methods of administration of donor stool include by enema, whole bowel 
irrigation through a nasogastric tube, or colonoscopy. By 2011, approximately 325 
cases of FMT had been reported worldwide, including approximately 75 % of them 
by colonoscopy or retention enema, and 25 % by nasogastric or nasoduodenal 
tube, or by esophagogastroduodenoscopy (Brandt and Reddy 2011, Gough et al 
2011). Posttransplant evaluations show resurgence of native Bacteroides species 
frequently missing in the flora of those afflicted with CDI (Khoruts et al 2010). In 
one series, a standardized filtered, frozen, and then thawed preparation of stool 
from pre-screened universal donors showed cure rates equal to or better than those 
from patient-identified donors (Hamilton et al 2013).
FMT appears to be safe, with no adverse effects or complications directly 
attributed to the procedure yet described in the existing literature (Bakken et al 
2011, Borody et al 2004). 
The availability of this treatment is limited, however. If FMT is considered, the 
donor should be screened for transmissible agents, and logistic issues need to be 
considered, including the timing, the collection and processing of the specimen from 
the donor and the preparation of the recipient. Despite reported overall success rates 
of approximately 90%, this approach continues to be underutilized for aesthetic 
and logistical reasons (Yoon and Brandt 2010).
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2.8.7 ROLe Of PRObIOtICS
Probiotics are living organisms that are beneficial to the host when given orally. 
Several individual trials using Saccharomyces boulardii, Lactobacillus species, 
or probiotic mixtures, always as an adjunct to antibiotics have indicated possible 
efficacy in preventing recurrent CDI. One uncontrolled study using Kefir (fermented 
milk drink made with kefir grains) as an adjunct to antibiotics did result in decreased 
recurrence of C. difficile (Bakken 2009). However, randomized-controlled trials 
have not demonstrated reproducible efficacy of probiotics in CDI prophylaxis or 
as primary treatment. (Na and Kelly 2011, Pillai and Nelson 2008). Thus, although 
probiotics demonstrate beneficial effects for other indications, they cannot be relied 
upon for prophylaxis against primary or recurrent CDI (Miller 2009). Probiotics 
are live organisms and treatment with probiotics is associated with risks, such as 
fungemia, bacteremia and endocarditis (Liong 2008). Probiotic Saccharomyces 
boulardii should not be given critically ill or immunocompromised patients 
(Enache-Angoulvant and Hennequin 2005).
2.8.8 ImmunOtheRAPy
The only currently available immunotherapy for CDI is pooled intravenous 
immunoglobulin (IVIG). IVIG preparations contain neutralizing levels of IgG 
antibody to toxin A and toxin B (Salcedo et al. 1997). No conclusive evidence of 
benefit for IVIG has been demonstrated in retrospective analyses of its use for 
treatment of RCDI,  nor has an effective dose been established (McPherson et al. 
2006, Wilcox 2004). In a phase II clinical trial, a single infusion of  monoclonal 
antibody to toxins A and B used as an adjuvant to standard antibiotic therapy 
significantly reduced the rates of RCDI compared to placebo (7% vs. 25%, p < .001) 
(Lowy et al. 2010). Additionally, this significant difference in recurrent rates was 
observed among patients with the C. difficile 027 strain and those with more than 
1 prior episode of CDI. 
An oral anti-Clostridium whey protein from cows immunized to C. difficile 
toxoid was studied in the Netherlands. Following successful studies in hamsters, 
the investigators found in an uncontrolled pilot study that anti-Clostridium whey 
protein was safe and well-tolerated in 16 patients with CDI (Young et al. 2007). 
None of the patients treated experienced recurrent CDI. Further development of 
this product has been halted due to lack of  funding.
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2.9 infeCtion Prevention and Control
The primary mode of C. difficile transmission is person-to-person spread through 
the fecal-oral route, mainly within inpatient healthcare facilities. Acquisition of 
C. difficile is facilitated by its ability to form spores. Spores may persist in the 
environment for months or years (Fekety et al. 1981) and they survive routine 
environmental cleaning with detergents and hand hygiene with alcohol-based gels.
Control measures of C. difficile are based on the prevention of cross-transmission, 
active surveillance of cases and prudent use of antimicrobial agents (Vonberg et 
al. 2008). Contaminated inanimate surfaces and transient hand carriage of health 
care workers and patients are important mediators for C. difficile transmission 
in hospitals (McFarland et al. 1989). Environmental disinfection, proper hand 
hygiene and the use of barrier methods are key components in preventing C. 
difficile transmission. Enhanced cleaning of all potentially contaminated surfaces 
with 10% sodium hypochlorite reduces the environmental burden of C. difficile. 
Hand washing with chlorhexidine or with soap and water has been shown to be 
effective in removing C. difficile spores from hands (Gerding et al. 2008). Other 
barrier precautions include use of gloves, gowns and contact precaution signs 
during patient contact.
Contact precautions for a patient with CDI should be maintained at a 
minimum until the resolution of diarrhea. One recommendation is to maintain 
contact precautions for 48 h after diarrhea ceases (Vonberg et al. 2008) or the 
whole duration of hospitalization (Muto et al. 2007). Prompt identification 
of patients with symptomatic C. difficile infection is essential to implement 
isolation precautions and treatment and to decrease the environmental bioburden 
associated with diarrhea.
Good antimicrobial stewardship complements infection control efforts and 
environmental interventions. A significant decrease in CDI rates was shown in 
a study by changing the class of antibiotics used as one-time doses for surgical 
prophylaxis (Al-Obaydi et al. 2010). Antimicrobials to be targeted ideally should be 
based on the local epidemiology and the C. difficile strains present, but restricting 
the use of  the clindamycin and cephalosporins have been the most effective. The 
results of fluoroquinolone restriction have been variable but may be of particular 
importance of outbreaks associated with the fluoroquinolone resistant strains (e.g. 
027). The efficacy of metronidazole or vancomycin prophylaxis to prevent CDI in 
patients who are receiving other antimicrobials is unproven, and treatment with 
these agents is ineffective against C. difficile in asymptomatic carriers (Gerding et al. 
2008). Several guidelines for antibiotic stewardship programs have been published 
(Dellit et al. 2007, Lucado et al. 2012, Davey et al. 2005). 
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CDI outbreaks are often multifactorial in terms of cause. One observational study 
issued a ‘‘bundle’’ on CDI prevention, consisting of education, increased and early 
case finding, expanded infection control measures, development of a C. difficile 
management team and antimicrobial stewardship (Muto et al 2005). As a quality 
improvement initiative, checklists facilitated implementation and adherence of new 
policies and practices. Hospital rates of C. difficile decreased from 7.2 cases per / 
1,000 discharges during  the year before institution of these measures to 4.8 cases 
per / 1,000 discharges in the subsequent 5 years. 
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3 aims of the study
The purpose of the present study was to investigate efficacy of different treatment 
modalities in recurrent Clostridium difficile infection and to characterize clinical 
feature and risk factors of extra-intestinal Clostridium difficile infection.
The specific aims were: 
I Compare Clostridium difficile immune whey (CDIW) with metronidazole 
for treatment of recurrent CDI
II Investigate the efficacy of fecal transplantation in treatment of recurrent 
CDI
III Assess the effectiveness of rifaximin in recurrent CDI
IV Characterize clinical features and risk factors of extra-intestinal CDI
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4 Patients and methods.
4.1 PAtIentS 
In Study I eligible patients were at least 18 years of age and had experienced at 
least 2 episodes of mild to moderate CDI within 3 months. During the second or 
later episode the subjects were randomized to the study. All patients had to have 
symptoms of CDI and were required to demonstrate a positive C. difficile toxin EIA 
assay, which was confirmed in Helsinki University Central Hospital Laboratory 
Diagnostics, HUSLAB. Written informed consent was obtained from all patients. 
The patients inclusions and exclusion criteria are characterized in detail in the 
original publication. Patients were recruited from December 2004 to March 2006 
at 10 centres in Finland. The centres were situated at Helsinki University Central 
Hospital (HUCH); Division of Infectious diseases, Central Hospital of Lapland, 
Rovaniemi, Turku University Hospital; Department of Internal Medicine, Helsinki 
City Hospital; Laakso Acute Care Hospital; Koskela Acute Care Hospital; Suursuo 
Hospital, Länsi-Uusimaa Hospital, Tammisaari, Oulu City Hospital, Turku Health 
Centre, and Satakunta Central Hospital, Pori.
In Study II all patients treated by FMT through colonoscopy were included in 5 
hospitals: HUCH, Turku University Central Hospital, Satakunta Central Hospital, 
Turku Municipal Hospital, and Helsinki Municipal Hospital, from November 2007 
though February 2010. The criterion for FMT was laboratory-confirmed RCDI 
(positive culture and toxin) despite antimicrobial treatment for CDI. All patients 
were refractive to standard therapy, and FMT was used as a salvage therapy after 
attempts of conventional therapy had failed. Only patients who had received FMT 
through colonoscopy according to the predetermined protocol using colonoscopy 
were included in the study. All the participating centres had electronic patient 
records including patient history, laboratory findings, and official information on 
the survival of the patient, which facilitated a reliable review.
In Study III all the patients who received rifaximin (Rifacol; Prodotti Formenti 
Srl, Milano, Italia) in HUCH, from March 2007 through December 2011 for CDI 
were included. Rifaximin was given only for RCDI. Information gathered from 
electronic patient records included patient history, laboratory findings, and official 
information on the survival.
In Study IV patients with extra-intestinal CDI were searched for in the electronic 
data files of the Division of Clinical Microbiology, HUSLAB. The laboratory which 
receives microbiologic samples from a population of 1.5 million analyzed all samples 
from patients that got the expenses covered by the community. The inclusion 
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criterion was detection of C. difficile in an extraintestinal sample analyzed between 
January 2002 and September 2012. Individual patient records were evaluated 
retrospectively in the archives of our hospital district.
4.2 StuDy DeSIgnS
Study I was a controlled, double-blind, randomized, parallel-group, multicentre, 
comparative trial of CDIW and metronidazole in the treatment of RCDI. The duration 
of the active period was 14 days in all patients. Patients were randomized to receive 
either CDIW 200 ml t.i.d and metronidazole placebo tablets t.i.d, or CDIW placebo 
liquid 200 ml t.i.d. and metronidazole tablets 400 mg t.i.d. The study consisted of 
4 visits and 2 follow-up contacts. All patients were seen by an investigator on d 0, 
7, and 14 and were seen or contacted by telephone on day 28 and 70. C. difficile 
culture and toxin test was performed on d 0, 14, and 28. Patients kept a daily stool 
and symptom diary for 42 days.
Study II and III were a retrospective review of patients. The symptoms were 
evaluated 12 weeks after the start of treatment and patient records were followed 
up until one year after the treatment.
In Study IV extra-intestinal CDI were searched for in an electronic database of 
all C. difficile positive isolates found during a 10-year period. The medical records 
were reviewed retrospectively. Disease severity and co-morbidities of the patients 
were evaluated using Horn disease severity and Charlson co-morbidity indexes.
4.3 DefInItIOnS
In Study I the patient was considered to be clinically cured if he or she became 
asymptomatic during the treatment course. Clinical failure was defined as persistent 
or recurrent symptoms and signs, and a need for new therapy during treatment 
or follow-up period.
In Studies II and III a treatment failure was defined as persisting diarrhea with 
a positive C difficile toxin stool test. 
In Study IV the severity of the disease was rated using the Horn index (Horn 
et al.1983). The Horn index is described in Table 3 (page 24). The severity of the 
underlying disease was scored using the Charlson index (Charlson et al. 1987), Table 
5. Points were added from each of the below listed co-morbidities.
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table 5  Age-adjusted Charlson index. 
One point Myocardial infarction, congestive heart failure, peripheral vascular disease, 
dementia, COPD, connective tissue disease, peptic ulcer disease, uncomplicated 
diabetes mellitus, mild liver disease. Age 41 to 50 years.
Two points Diabetes mellitus (if end-organ damage), moderate to severe chronic kidney 
disease, hemiplegia, leukemia, malignant lymphoma (solid tumor).  
Age 51 to 60 years.
Three points Moderate to severe liver disease. Age 61 to 70 years.
Four points Age 71 or older
Six points AIDS
4.4 StuDy tReAtmentS
In Study I patients were treated either with CDIW or metronidazole. CDIW was 
manufactured by immunization of cows in their gestation period with inactivated 
C. difficile vaccine. The resulting colostrum was processed, immunoglubulins 
were concentrated and the end-product containing high titres of C. difficile 
immunoglobulin was used as CDIW. The production process is characterized in 
detail in the original publication. Whey made from colostrum from unimmunized 
cows was used as a negative control, which consistently gave no activity against C. 
difficile. Metronidazole and metronidazole placebo were both in the form of white 
capsules.
In Study II 70 patients were treated by FMT, which was performed via 
colonoscopy after colonic lavage. The patients were pretreated with vancomycin 
or metronidazole until a reduction of symptoms occurred. This treatment was 
discontinued an average of 36 hours before the transplantation. Colonic lavage 
was performed by oral ingestion of 4 L of a polyethylene glycol solution (Colonsteril; 
Orion Oyj, Espoo, Finland). During endoscopy no evident contraindications for 
fecal transplantation could be observed in any of the patients prepared for the 
transplantation. Biopsy specimens were taken when considered appropriate by the 
endoscopist. The patients were given instructions for home cleaning and disinfection 
to reduce the possibility of C. difficile re-infection at home.
All donor stools were freshly passed. Sixty-one of the stool donors were close 
relatives or other household members. In the remaining 9 cases, family members 
were not eligible or available as donors, and a healthy volunteer donated the stool. 
There were no food restrictions or recommendations for donors. Preparation of 
donor stool and the patient for the procedure is presented in Table 2 in the original 
publication. Individuals who had not received antimicrobial therapy for the past 
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6 months and who did not have any intestinal symptoms were considered to be 
suitable for stool donation. Preferred stool donors were as follows: (1) relatives, (2) 
individuals who had intimate physical contact with the patients (spouse or significant 
partner), or (3) any other healthy donors. Our protocol for donor screening is 
summarized in Table 1 in the original publication.  
In Study III standard rifaximin treatment was oral rifaximin 400 mg twice a day 
for 14 days that was preceded by an oral course of vancomycin 125 mg four times 
daily for 14 days. This standard treatment was given to 25 patients. One patient got 
vancomycin tapering for 6 weeks before the oral course of rifaximin. Three patients 
got metronidazole 400 mg three times daily for 14 days instead of vancomycin 
before rifaximin. One patient got both metronidazole and vancomycin before the 
rifaximin therapy. Two patients got oral rifaximin 400 mg twice a day for 28 days 
without any immediately preceding courses of vancomycin or metronidazole.
4.5 mICRObIOLOgICAL methODS
In Study I toxin test used in each centre was confirmed in the Helsinki University 
Laboratory, HUSLAB, by C. difficile toxin EIA assay (Premier Toxins A & B; Meridian 
Bioscience).
In Study II C. difficile culture and toxin test were done by each centres own 
laboratory. Strain typing of isolated C. difficile colonies was performed using the 
DiversiLab system (bioMérieux, Marcy l=Etoile, France). This method is based on 
PCR amplification of repetitive extragenic palindromic sequences and it reliably 
can distinguish C difficile ribotype 027 strain from other strains.
In Study III C. difficile isolation was performed by culturing fresh stool samples 
on C. difficile selective CCFA agar (cycloserine-cefoxitin-fructose-egg yolk agar) 
at 35° C for 42 h in anaerobic atmosphere. Colonies with typical morphology, 
fluorescence, and odour were identified as C. difficile. Toxin production was 
analysed directly from faecal samples with the Premier Toxins A&B-test kit 
(Meridian; Bioscience Inc., Cincinnati, OH, USA) during 2007–2010 and with 
VIDAS C. difficile Toxin A & B CDAB-system (bioMerieux, Marcy l’Etoile, France) 
from 2011 onwards according to the manufacturer’s instructions, or if the direct 
toxin test was negative, from C. difficile colonies. Strain typing was performed by 
DNA analysis using multiplex PCR. Antibiotic susceptibilities for metronidazole, 
vancomycin, and rifampin (reflecting the susceptibility for rifaximin) were 
determined with E-tests (bioMerieux) on Fastidious Anaerobe Agar (FAA)-plates 
(LabM, Lancashire, UK).
In Study IV C. difficile was isolated in extra-intestinal sites using conventional 
anaerobic bacteriologic techniques. These were not specifically designed to detect C. 
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difficile but rather designed to detect all anaerobic microbes. After transportation 
in Stuart transportation media the samples were streaked on FAA-plates (Lab M, 
Bury, United Kingdom) that were supplemented with 5% defibrinated horse blood. 
The plates were then incubated in anaerobic jars at 35°C. Isolation of C. difficile 
from peripheral blood samples was performed using the BacT/ALERT® Culture 
Media system for blood samples (bioMérieux, Marcy l’Etoile, France). Isolation of 
C. difficile in stool samples was performed using C. difficile selective CCFA at 35°C 
for 42 h in anaerobic atmosphere. Colonies with typical morphology, fluorescence, 
and odor were presumptively identified as C. difficile. Bacterial isolates were 
identified by biochemical tests. C. difficile toxins were detected directly from 
C. difficile colonies by the Premier Toxins A&B-test kit (Meridian; Bioscience 
Inc., Cincinnati, OH, USA) during 2007–2010 according to the manufacturer’s 
instructions. From 2011 onwards the toxin genes were analyzed from C. difficile 
colonies with multiplex PCR (Antikainen et al. 2009). Strain typing when done 
was performed by DNA analysis using multiplex PCR (Antikainen et al. 2009).
4.6 ethICAL ASPeCtS
In Study I, the protocol and consent form, which was conducted in accordance with 
the declaration of Helsinki and all applicable laws and regulations, were approved 
by the Finnish Agency for Medicines (EudraCT 20004-000499-16) and by an 
institutional review board of the ethics committee at each of the centres.
In Study II, FMTs and the retrospective review of the patient records were 
approved by the institutional review boards of all the participating centres. All 
patients were informed about the experimental nature of this treatment procedure 
and about the available results in other previously published reports and possible 
risks of the procedure. All of the patients provided informed consent.
Studies III and IV were approved by the Institutional Review Board of HUCH.
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5 results
5.1 PAtIent ChARACteRIStICS (I-III)
Patient characteristics and response to therapy are described in Table 6. In Study I 
total of 40 patients underwent randomization and 38 were included in the modified 
intention-to-treat population. Two patients were excluded from the efficacy analysis, 
one patient because the C. difficile toxin test was negative and another because the 
patient died on the second day on CDIW. However, the latter patient was included 
into the safety part of study and reported as a serious adverse event. All 38 patients 
were compliant with therapy, defined as >90% adherence to the assigned 14-d 
treatment regimen. 
In Study II the mean time between the diagnosis of CDI and the initial stool 
transplantation was 133 days (range, 46–360 days). The patients had an average 
of 4.5 courses of antibiotics for CDI before FMT (range, 2–12). These treatments 
included a variety of metronidazole, vancomycin, and rifaximin regimens, and 
one patient also received intravenous immunoglobulin therapy. The baseline 
characteristics varied slightly according to the hospital. In one tertiary care 
university hospital there were more young patients (5 of 11 were younger than age 
40), and all were outpatients. In secondary care municipal hospitals the patients 
were, on average, older, and there also were inpatients. Most patients had received 
antibiotics commonly associated with the risk of developing CDI, remarkably often 
cephalosporins (47 of 70). One nurse developed an occupational C. difficile strain 
027 infection after having taken care of a patient with a 027 strain. There were 2 
peripartum CDIs.
None of the 70 patients had definitive signs of IBD at colonoscopy. In some 
patients microscopic evaluation showed mild epithelial damage, edema, and 
scattered neutrophilic infiltrate. One patient was found to have adenocarcinoma 
of the colon at colonoscopy. Her C. difficile non-027 infection resolved after FMT 
but she died of the carcinoma 3.5 months after the transplantation.
In Study III the preceding infections and antibiotics before the initial CDI 
are given in Table 1 in the original publication. Antibiotic susceptibilities were 
determined of isolates from 22 patients. Most isolates (15 of 22, 68%) had very 
low MIC-values for rifampin (<0.002 lg/mL). Those strains with the DNA profile 
compatible with the virulent 027 ribotype had, on the average, more than 10-fold 
higher MIC for rifampin than other strains (Table 2 in the original publication). 
The average MIC of metronidazole was approximately 2-fold higher in 027 strains 
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than other strains. There was no evident difference in the average susceptibilities 
to vancomycin between 027 and non-027 strains. 
table 6  Patient characteristics and treatment outcomes of the Study (I-III) patients
Cdiw
( study i )
metronidazole 
( study i )
fmt
( study ii )
rifaximin
( study iii )
No. of patients 18 20 70 32
Age mean 56 66 73 58
Age, range 22-85 25-92 22-90 19-88
Gender, male 7 (39%) 11 (55%) 28 (40%) 13 (41%)
Gender, female 11 (61%) 9 (45%) 42 (60%) 19 (59%)
Number of previous 
CDI episodes(range)
2.39 (1-4) 2.15 (1-4) 3.5 (1-12) 4.3 (2-12)
027 strain NA* NA* 36/70=51 % 8/27= 30%
Outpatient 17/18 18/20 60/70 NA
Response to therapy ** 10/18 (56%) 18/20 (55%) 66/70 (94%) 17/32 (53%)
** In Study I two of the total 38 patients (5%) had a 027 strain (unpublished)
* in Study I 10 weeks, in Study II-III 12 weeks
5.2 ReSPOnSe tO theRAPy  
Summary of the response to therapy is described in Table 6. In Study I the response 
rates by primary end-points to study drugs are shown in Table II in the original 
publication. No statistically significant differences were observed across the 2 
treatment groups. None of the patients on metronidazole and 3 patients on CDIW 
received an open label treatment for CDI during the 2-weeks study medication 
period. After the treatment period and during the 70-d follow-up, 5 patients in the 
CDIW group and 9 in metronidazole group experienced a relapse, which needed an 
open-label re-treatment of CDI. At the end of the study 8 of 18 patients (44%) with 
CDIW and 9 of 20 (45%) with metronidazole experienced relapse. Kaplan-Meier 
estimates of relapse-free survival are shown in Figure 2 in original publication.
There were no differences between the study groups with regard to need of 
hospitalization. Of 13 patients hospitalized, CDIW was used in 7 and metronidazole 
in 6. The period of hospitalization was 4.8 and 4.5 days, respectively. Readmission 
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to hospital because of CDI was needed for 1 patient in the CDIW group and 2 in 
the metronidazole group. On day 14, eradication of C. difficile (toxin negative) was 
demonstrated in 6 of 15 patients (40%) receiving CDIW and in 11 of 18 patients 
(61%) receiving metronidazole. On day 20, six of 11 (55%) patients of the CDIW 
group and 10 of 13 (77%) of the metronidazole group showed eradication.
In Study II during the first 12 weeks of follow-up evaluation after the FMT 
resolution of symptoms was seen in all 34 (100%) patients with CDI due to a non-027 
strain. Of the 36 patients with CDI due to a 027 strain, 32 (89%) had a favourable 
response. All 4 nonresponders with 027 C. difficile infection had serious conditions 
and died 1.5–3 months after the FMT. One patient had an especially severe CDI 
and was offered colectomy as a treatment option. He refused surgery and FMT was 
used as a salvage therapy. The second patient with a severe CDI had an incomplete 
pretransplantation lavage, did not have any response to FMT, and died of CDI 2 
months after the FMT. The third patient had chronic obstructive pulmonary disease 
and developed severe diarrhea and died of CDI. The common feature of these  3 
patients was an especially aggressive CDI due to ribotype 027. The fourth patient 
had end-stage myeloma. She had RCDI after antibiotic treatments for pneumococcal 
septicemia and meningitis shortly after FMT. She got the second FMT 24 days after 
the first procedure but subsequently died of myeloma related uremia. In study II 
during the 1-year follow-up period, 4 patients with an initial favourable response 
had a relapse after receiving antibiotics for unrelated causes. Two of these patients 
were treated successfully with another FMT and 2 were treated successfully with 
antibiotics for RCDI.
In Study III during 12 weeks follow up period, 17 (53%) patients had no relapse. 
There was a trend that those patients (75%, 6 of 8) who had C. difficile  027 strain 
tended to have a relapse more frequently than those who had a non- 027 strain 
(42%, 8 of 19), but this trend was not statistically significant (P = 0.11,Fisher exact 
test). MIC value of rifampin predicted the response to rifaximin treatment (P = 
0.0461, Mann–Whitney U-test). All the 12 patients who were cured had isolates 
with rifampin MIC values below 0.3 µg/mL, whereas 5 of the 10 patients who 
failed had a MIC value above this value (P = 0.010 Fisher exact test). When the 
epidemiological cut-off value of 0.004 µg/mL was used, which is considered to 
distinguish wild type C. difficile isolates from isolates with reduced susceptibility 
to rifampin according to EUCAST (The European Committee on Antimicrobial 
Susceptibility Testing -http://www.eucast.org), we get an OR 4.62 (95% CI: 0.52–
65.4, P = 0.172) of risk of failure.
During the subsequent year, none of the 17 patients who responded to rifaximin 
developed CDI. Of the 15 who had a failure after rifaximin therapy, 8 patients 
recovered after receiving faecal transplantation. Two patients recovered after 
receiving a course of metronidazole. Four patients recovered after receiving one 
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or repeated courses of vancomycin. One patient ultimately recovered after receiving 
continuous vancomycin for 3 years.
5.3 ADveRSe eventS 
In Study I adverse events were recorded in 10 of 20 patients receiving metronidazole 
and 12 of 18 patients receiving CDIW. The adverse events were mild and did not 
cause the cessation of study drugs. Only 2 adverse events were likely to be related 
to the investigational medicine, both in the metronidazole group, one metallic taste 
and one nausea. Two serious adverse events (SAE) were reported. Both were in 
the CDIW group. A patient with complicated diabetes and heavy coronary artery 
disease succumbed and 1 patient was readmitted to hospital because of Escherichia 
coli bacteraemia. None of these events was thought to be related to the study drug. 
In both cases, the causality of SAEs was classified by the reporter as unlikely to be 
due to the investigational product.
In Study II no immediately evident complications of FMT were observed. There 
were no reported transmitted infections. Four patients infected with the ribotype 
027 strain did not respond to FMT and died within 3 months. No evidence could 
be shown that the death of these patients could have been caused or facilitated by 
intestinal lavage, colonoscopy, or FMT.  Except for these 4 patients, none of our 
patients had any severe adverse events that could be related to FMT. In addition 
to these 4 patients,10 patients died of unrelated illnesses during the 1-year follow-
up period.
In Study III no obvious side effects were observed during the rifaximin therapy.
5.4 extRA-InteStInAL CDI 
We found altogether 31 patients (only 0.17% of all CDIs) with extraintestinal 
CDI in the databases during the 10-year study period. Examination of the patient 
records revealed that the patients could be categorized in to five different infection 
types: bacteremic infections (2 patients), abdominal infections without any prior 
surgery (4 patients), abdominal infections after surgery (7 patients), perianal 
abscesses (4 patients) and wound infections (13 patients). The number of extra-
intestinal CDIs ranged from none to six cases per year. In most instances (26 out 
of 31, 85%) C. difficile was isolated together with other microbes. Strain typing 
was done of 9 isolates and 2 (22%) of these had a DNA profile compatible with 
the 027 ribotype.
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The majority (24 out of 31, 77%) of patients had a Horn index 3 or 4 indicating a 
severe or fulminant disease. Many patients had severe underlying diseases and the 
mean Charlson index was 5.2. All patients had received antibiotics before developing 
an extra-intestinal CDI. Majority (81 %) of patients  developed the infection when 
hospitalized. One-year mortality rate was 36% (11/31). One –year mortality was 
associated with both the Horn (p=0.01) and Charlson indexes (p<0.001). Patients 
with perianal abscesses tended to be younger and had lower Horn and Charlson 
indexes than the other patients (p<0.05, ANOVA). Nine patients (29%) were alcohol 
abusers to the extent that they had severe adverse effects related to alcohol abuse 
such as liver cirrhosis or pancreatitis. All the two patients with bacteremic infections 
had diarrhea and 14 of the remaining patients had clinical symptoms of a manifest 
diarrhea. 
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6 disCussion
6.1 CDIW AnD metROnIDAzOLe fOR ReCuRRent CDI 
CDIW is a nonantibiotic modality, which is based on orally ingested specific 
C. difficile-enriched bovine immunoglobulins. The present study was the first 
randomized, double-blind study where CDIW was compared to standard treatment.
The results of this study demonstrate that the efficacy of CDIW in the treatment 
of mild-to moderate recurrent CDI seems to be similar to that of metronidazole 
(sustained recovery 56% vs. 55%). 
The effect of bovine antibody-enriched whey on CDI has been previously 
investigated (van Dissel et al. 2005, Numan et al. 2007) in Netherlands. In an 
open uncontrolled study, 101 patients (109 CDI episodes) received after completion 
of at least 10 days of standard antibiotic treatment (metronidazole or vancomycin), 
daily treatment with immune milk for 2 weeks (Numan et al. 2007).  The follow-
up period lasted 60 days. 64% of patients suffered their first episode of CDIW. In 
total, 11 (10%) of 109 episodes were followed by a relapse of CDI.  In contrast to 
that study, our study was a double-blind and controlled study, using a colostrum-
based product instead of immune milk, and CDIW in the absence of antibiotics. 
Compared to the latter study (Numan et al. 2007) the present study was also more 
homogeneous with regard to patient material, all patients suffering from recurrent 
CDI. Thus the 2 studies are not comparable in terms of patient selection, the planning 
of the studies, use of previous antibiotic treatment, and immune whey product. 
45% of patients of either the CDIW or the metronidazole group failed. This 
degree of failure may reflect the feature of the study population that many of the 
patients included into our study had more than 1 recurrence of CDI. Nevertheless, 
the results were in line with a previous report of antibiotic treatment of recurrent 
CDI (McFarland et al. 2002). 
The mechanism of action of CDIW is unclear. The specific antibodies may 
bind toxins or prevent mucosal damage caused by toxins. CDIW may prevent 
the adhesion of C. difficile to mucous membranes. However, the mode of action 
of metronidazole and CDIW are different. CDIW as an immunomodulatory does 
not  directly inhibit the growth of C. difficile. CDIW is an interesting alternative to 
conventional antibiotic treatment in patients with recurrent CDI. CDIW does not 
alter normal colonic bacterial flora as antibiotics do and does not cause resistance 
problems.
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6.2 feCAL mICRObIOtA tRAnSPLAntAtIOn  
fOR ReCuRRent CDI  
FMT is a strategy that restores the diversity of the gut microflora, which may confer 
protection against toxigenic C. difficile. In Study II 70 patients with RCDI were 
treated with FMT and followed up retrospectively for one year. Sixty-six of 70 
patients (94%) recovered, which is an outstanding result in a patient group refractory 
to other treatment methods. In Study I patients,  who had, on average, a milder 
disease of RCDI, only 55% recovered with metronidazole and 56% with CDIW 
during a 70-day follow-up period. Study II also included patients who were treated 
successfully with FMT after having failed rifaximin or  intravenous immunoglobulin 
therapy. 
C. difficile ribotype 027 is associated with a more severe diarrhea and with 
more recurrences (Goorhuis et al. 2008). In a recent study, a new macrocyclic 
antibiotic, fidaxomicin, was compared with vancomycin in the treatment of CDI 
(Louie et al. 2011). CDI recurred significantly less often with fidaxomicin than with 
vancomycin (15% vs. 25%) during 4 weeks of follow-up evaluation. However, among 
patients with C. difficile ribotype 027 infection, fidaxomicin appeared to be no 
better than vancomycin in preventing recurrences. The recurrence rates were 24% 
and 23%, respectively. In the present study, only 4 (11%) of our 36 patients with 
C. difficile ribotype 027 infection developed a recurrence during the 12 weeks of 
follow-up evaluation after FMT as compared with the recurrence rate of 24% after 
the fidaxomicin treatment after 4 weeks of follow-up evaluation in the previous 
study. Although the characteristics of the patients may be different in our study 
as compared with that of the fidaxomycin study and, therefore, the results are not 
directly comparable, our study shows that FMT is an effective treatment option 
for recurrent CDI and also for recurrent CDI caused by the virulent C. difficile 
ribotype 027.
Four of our patients had CDI diarrhea despite FMT and died shortly after the 
transplantation. All 4 of these patients were seriously ill already before FMT and 
the procedure was used as salvage therapy. Up to a 23% overall mortality rate has 
been reported with CDI at 30 days (Pepin et al. 20053). Thus, the mortality rate in 
our study does not appear to be greater than in some previously reported series, 
suggesting that FMT itself seems to be a rather safe procedure. FMT seems to be 
safe also for patients with underlying serious conditions. Our study included one 
immunosuppressed lung transplantation patient who had a favourable response 
after FMT. Also, a patient with a fulminate life-threatening CDI has been treated 
successfully with FMT (You et al. 2008).
Performing FMT by colonoscopy has the advantage that it enables differential 
diagnostics of long lasting diarrhea, for example, to exclude IBD, which is a risk 
54
factor for CDI (Mylonaki et al. 2004, Issa et al. 2008, Rodeman et al. 2007) and 
to detect diverticulosis of the colon and colon carcinoma, which may be masked 
by CDI. The lavage before the colonoscopy conceivably results in a reduced colonic 
biomass, which may have facilitated the restoration of the colonic bacterial flora by 
the transplant. We recommend using fresh instead of frozen donor stool transplant 
because bacteria are presumably more viable in fresh stool, despite good results that 
also have been published using a frozen donor stool transplant (Jorup-Ronstrom 
et al. 2006). There have been concerns regarding the risks, including perforation 
induced by colonoscopy in patients with active colitis. All of our patients were 
pretreated with antibiotics for CDI, which probably reduced inflammation, and 
possibly also the risk of perforation at the time of colonoscopy. The colonoscopy 
technique used seemed to be safe because none of our patients had any severe 
immediate adverse events that could be related directly to colonoscopy.
The principal potential risk associated with FMT is transmission of contagious 
agents contained in the donor stool. There are risks of transmitting agents that 
do not cause a disease immediately after transplantation, but may complicate the 
treatment of the patient in the future. Such agents may include multidrugresistant 
gram-negative bacteria. We suggest that tests be conducted to detect possible 
multidrug-resistant bacteria in donor stool to maximize the safety of the procedure. 
Despite evident risks associated with FMT, no reported transmitted infections or 
significant immediate adverse effects have been reported to date. Although we did 
not systemically search for transmitted infections in our patients, we have so far not 
found any clinical evidence of transmitted infections related to the fecal transplant.
6.3 RIfAxImIn fOR ReCuRRent CDI
The outcome after rifaximin in patients with RCDI was promising as 17 (53%) of 
the 32 patients responded favourably. Although the treatment in almost all patients 
was preceded by a course of vancomycin or metronidazole, rifaximin most likely 
contributed to the cure, as there was an association between the susceptibility of C. 
difficile isolates to rifampin and clinical outcome. Nevertheless, it should be noted 
that in our series, the course of metronidazole or vancomycin, that immediately 
preceded the administration of rifaximin, probably had an important role in the 
cure rate. Rifaximin therapy seemed to be safe as none of our patients experienced 
any notable side effects during rifaximin treatment.
Despite this, our results were not as effective as reported previously for rifaximin 
in CDI. In an earlier prospective trial on patients with mild-to-moderate CDI, all 
16 patients (100%) who completed treatment with rifaximin recovered from the 
infection (Basu et al. 2010). In another series of 8 patients with RCDI who received 
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rifaximin, 7 patients (88%) experienced no further diarrhoea recurrences and the 
patient who had a recurrence subsequently responded favourably to a second course 
of rifaximin treatment.(Johnson et al. 2007). In yet another study of 6 patients with 
recurrent CDI who received rifaximin, 4 (66%) patients had no further diarrhoea 
episodes (Johnson et al. 2009). Finally, in a randomized placebo-controlled trial 
where rifaximin was given immediately after standard antimicrobial therapy for 
CDI, 26 (79%) of the 33 patients responded favourably (Garey et al. 2011). Taken 
together, the overall cure rate of 85% of all the 63 patients in the above four studies 
is clearly higher than the cure rate of 53% of our 32 patients.
It is possible that our patients were on the average more prone to relapses, 
which might have contributed to a less favourable response as compared with the 
results reported previously. All our patients who received rifaximin had RCDI. This 
was because our standard treatment for the first episode of CDI is metronidazole 
or vancomycin, which is consistent with current recommendations (Bauer et al. 
2009, Cohen et al. 2010). There may have been a selection in our series for those 
patients who were more prone to have relapses. Increased age, initial disease 
severity, and hospital exposure have been predicted to predict CDI recurrence (Gujja 
and Friedenberg  2009, Eyre et al. 2012), the use of proton pump inhibitors have 
been implicated as a risk factor for the development of CDI (Bavishi and DuPont 
2011) and factors such as increased age, low serum albumin level and high serum 
creatinine level have been associated with the severity of the disease (Khanna et 
al. 20121 , Ananthakrishnan et al. 2012). We attempted to analyse whether such 
factors would reveal any association with the success of rifaximin treatment, but 
our series was too small to address this.
Of note was that the MIC value of rifampin, although all the MIC values of our 
strains were rather low, seemed to predict the response to rifaximin treatment. This 
may imply that sensitivity testing may be used to select patients with extremely low 
MIC values for rifaximin treatments. On the other hand, there was a correlation 
between the 027 strain type of C. difficile and an increased MIC value of rifampin 
as well as to metronidazole that have also been observed in earlier studies (Hecht 
et al. 2007, Citron et al. 2009, Huang et al. 2010, Goldststein et al. 2011). Thus, 
specific pathogenic factors of the 027 isolates may be responsible for the difference 
in the cure rate and not necessarily the low MIC value. Nevertheless, rifaximin may 
be more efficacious against 027 strains with extremely low MIC values of rifampin 
than against other strains.
Development of resistance against rifaximin is a potential concern. Prior 
exposure to rifamycins has been reported to be a risk factor for rifampin-resistant 
CDI (Curry et al. 2011) and rifaximin resistant C. difficile strains may emerge even 
during therapy (Johnson et al. 2009, Carman et al. 2012). Although the rate of 
rifaximin resistance among C. difficile isolates has been as low as 2% (Jiang 2010), 
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the rate of resistance may reach 20% (Miller et al. 2011²) and rifamycin-resistant C. 
difficile strains have been reported to cause hospital outbreaks (Curry et al. 2009). 
Of concern are also reports that suggest that the antibiotic resistance of C. difficile 
may be changing to the worse (Spigaglia et al. 2011). These issues on resistance 
restrict the use of rifaximin in CDI and highlight the importance of sensitivity testing 
of C. difficile isolates. Despite this, rifaximin has a reasonable effect in CDI and it 
can be considered as an optional treatment for RCDI. 
6.4 extRA-InteStInAL CDI
Extra-intestinal CDIs were rare. Only 31 cases were found during the 10-year period
studied in our hospital district that provides health care to a population of ca. 1.5 
million. The number of cases was low (0.17% of all CDIs) as compared to all patients 
with CDI during the same time period. The numbers of extra-intestinal C. difficile 
cases observed would translate to a mean yearly incidence of 0.2 per 100.000. This 
may, however, be an underestimate as C. difficile may be difficult to isolate and the 
rate of recovery may vary depending on the isolation method (Carrol and Bartlett 
2011). It should be noted that C. difficile was isolated in most cases together with 
other microbes, which may make the isolation of C. difficile even more demanding. 
Detection of C. difficile in extra-intestinal sites remains a challenge and emphasizes 
the need for sensitive microbiologic detection methods.
A common feature of extra-intestinal CDI was that most patients were 
hospitalized and had received antibiotics, which increase the risk of C. difficile 
carriage. The patients may or may not have clinical symptoms of diarrhea but 
many had severe comorbidities, previous surgery, or intestinal infection. Such 
characteristics have also been observed in previous reports (Wolf et al. 1998, Gerard 
et al. 1989). Most of the patients in our series had high Charlson co-morbidity 
and Horn disease severity indexes, which reflect the morbidity of our patients. 
Mortality was high and it correlated with these indexes.
A significant proportion of our patients were alcohol abusers. Alcohol abuse has 
been reported also in previous reports on extra-intestinal CDIs (Garcia-Lechuz et al. 
2001, McGill et al. 2011). It has recently been found that a subgroup of alcoholics 
has dysbiosis with an altered colonic microbiota with lower median abundances 
of Bacteroidetes and higher ones of Proteobacteria (Mutlu et al. 2012). Lower 
abundances of Bacteroidetes have also been observed in the intestinal flora of 
patients with CDI enteritis (Manges et al 2010) suggesting some similarity in 
the intestinal flora of alcohol abusers and patients with CDI. Such changes in 
the intestinal microbiota of alcohol abusers may increase the risk of C. difficile 
colonization. It is also possible that alcohol abuse or diseases due to alcohol abuse 
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may suppress immune responses, which could increase the risk of C. difficile 
colonization and infection.
Treatment of CDI enteritis is shifting towards local therapy such as to the use 
of per oral non-absorbable antibiotics vancomycin, rifaximin, and fidaxomycin as 
well as to the use of FMT (Lo Vecchio and Zacur 2012, Pepin et al. 2007) . The 
occurrence of deep extra-intestinal CDIs implies that there is still need for systemic 
antibiotics in selected cases of severe C. difficile colitis.
It can be concluded that extra-intestinal CDIs are rare and occur in hospitalized 
patients who often have severe co-morbidities. C. difficile is usually isolated together 
with other microbes but may also be the single microbe of the infection. Most extra-
intestinal CDIs are localized in the abdominal area and result either from intestinal 
perforation after infection or leakage after surgery. C. difficile wound infections may 
result from contamination by feces. C. difficile can cause bacteremia and it may 
enter distant sites through transient bacteremia.
6.5 RemAInIng ChALLengeS
Treatment of CDI has relied primarily on metronidazole and vancomycin for the 
past 30 years. Limitations of these agents have stimulated the development of newer 
therapies. In the present study we have investigated the treatment of recurrent CDI 
with antibiotics (metronidazole and rifaximin), passive immunotherapy (CDIW) 
and bacteriotherapy with FMT. Although these treatment modalities were not 
directly compared to each others, FMT appears to be the most potent treatment 
of recurrent CDI. Sixty-six of our 70 patients (94%) recovered with FMT. Our 
results are similar to previous data on FMT with mean cure rates approximately 
91 % (Gough et al. 2012).
In spite of growing interest in FMT, many questions and challenges remain. 
Comparative studies are needed to address which route of transplantation is the 
most appropriate for various presentations of CDI. In addition, future metagenomic 
studies of colonic microbiota may reveal clues of the specific microbes or microbe 
classes required to suppress CDI. There are risks of transmitting agents that do 
not cause a disease immediately after transplantation, but may complicate the 
treatment of the patient in the future. Long-term studies after FMT need to be 
performed to address transmission of contagious agents contained in the donor 
stool and  other possible long term side-effects.
Recent advances suggest that effective donor microbiota can be produced by 
repeated filtering, washing, freezing and even freezedrying feces – and yet still deliver 
a clinical result equivalent to that of fresh crude fecal homogenate when treating 
CDI (Hamilton et al. 2012, Hamilton et al. 2013) while removing the fecal odour. 
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The use of feces may be eliminated in favour of defined mixtures of cultured bacteria 
that confer colonization resistance against C. difficile. In the future, lyophilized full 
spectrum human donor microbiota or mixtures of key bacteria may be available 
in capsule formulation to treat CDI  and perhaps be used routinely after antibiotic 
usage to prevent gut flora damage.
Active rather than passive immunization is an attractive goal for effective 
and durable protection against CDI. Both passive immunity with monoclonal 
antibodies and vaccines are currently undergoing clinical trials involving humans. 
Preliminary evidence shows higher serum antitoxin antibody levels in vaccinated 
patients than in those exposed naturally to CDI (Aboudola et al 2003). Vaccine 
was used in combination with antibiotics to successfully treat three patients with 
RCDI (Sougioultzis et al 2005). Major questions regarding the immune response to 
vaccine in elderly populations, the magnitude and duration of vaccine protection, 
and the selection of an appropriate at-risk population for vaccination remain to 
be answered.
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7 summary and ConClusions  
The main results of the present study can be summarized: 
I Efficacy of CDIW in the treatment of mild-to moderate RCDI seems to be 
similar to that of metronidazole. CDIW did not cause systemic or local side-
effects.
II FMT through colonoscopy seems to be an effective treatment for RCDI and 
also for RCDI caused by the virulent C. difficile 027 strain. Colonoscopy is 
a feasible technique for FMT, which seems to be safe also for patients with 
underlying serious conditions.
III Rifaximin has a reasonable effect in CDI and it can be considered as an optional 
treatment for RCDI. Rifaximin may be more efficacious against non-027 
strains with extremely low MIC values of rifampin than against other strains.
IV Extra-intestinal CDIs occur mainly in hospitalized patients with significant 
comorbidities. Most extraintestinal CDIs are localized in the abdominl area
 and result either from intestinal perforation after infection or leakage 
after surgery. C. difficile can cause bacteremia and may enter distant sites 
through transient bacteremia. C. difficile wound infections may result 
from contamination by feces. Mortality of extra-intestinal CDIs is high and 
associated with underlying diseases .
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